Product EMA FDA EN Other WHO Year Generic DrugBank ID ATC ChEMBL Indications Targets Last Update Abemaciclib Y Y N N 2017 N DB12001 L01EF03 CHEMBL3301610 Advanced Breast Cancer; Metastatic Breast Cancer CCND2; KRAS; CDK4; CDK6; NRAS; PIK3CA; CDKN2A; ESR1; BRAF; SMARCA4; CCND3; ERBB2; CCND1; PGR; TP53; ESR2 2024-02-07 Abiraterone Y Y N Y 2011 Y DB05812 L02BX03 CHEMBL254328 Metastatic Castration Resistant Prostate Cancer CYP17A1; CHEK2; PTEN; CDK12; TSPYL1; ATM; SRD5A1; SRD5A2; PALB2; SRD5A3; BRIP1; APC; DSE; TP53; YBX1; FANCA; AR 2024-02-07 Acalabrutinib Y Y N N 2017 N DB11703 L01EL02 CHEMBL3707348 Chronic Lymphocytic Leukaemia (CLL); Mantle Cell Lymphoma (MCL); Small Lymphocytic Lymphoma BTK; TP53 2024-02-07 Aclarubicin N N N Japan N DB11617 L01DB04 CHEMBL502620 CSF2; SMN1; TOP2A 2024-02-07 Adagrasib N Y N N 2022 N DB15568 L01XX77 CHEMBL4594350 Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer KRAS 2024-02-07 Afatinib Y Y N Y 2013 N DB08916 L01EB03 CHEMBL1173655 Metastatic Non-Small Cell Lung Cancer; Refractory, metastatic squamous cell Non-small cell lung cancer ERBB2; EGFR; ERBB4; PIK3CA; ROS1; EML4; ERBB3; PTEN; NRG1; BRAF; KRAS; ALK 2024-02-07 Aflibercept Y Y N N 2011 N DB08885 S01LA05; L01XX44 CHEMBL1742982 Metastatic Colorectal Cancer (MCRC) VEGFB; PIGF; PGF; VEGFC; VEGFA 2024-02-07 Aldesleukin N Y Y N 1992 N DB00041 L03AC01 CHEMBL1201438 High Risk Neuroblastoma; Metastatic Melanoma; Metastatic Renal Cell Carcinoma IL2RB; IL2RA; IL2; IL2RG; CD40; EPCAM 2024-02-07 Alectinib Y Y N N 2015 N DB11363 L01ED03 CHEMBL1738797 Refractory, metastatic Non small cell lung cancer RET; ALK; ROS1; BRAF; TP53; EML4 2024-02-07 Alemtuzumab Y Y N N 2001 N DB00087 L04AA34 CHEMBL1201587 B-Cell Chronic Lymphocytic Leukemia; T-Cell Prolymphocytic Leukemia CD52; TP53; CXCL12 2024-02-07 Alitretinoin Y Y N N 1999 N DB00523 D11AH04; L01XF02 CHEMBL705 CD34; RXRB; RARG; ERBB2; RARB; RXRA; CETP; VDR; CCR2; SFTPA1; RXRG; P2RY2; SERPINE1; EHMT2; CGA; RARA 2024-02-07 Alpelisib Y Y N N 2019 N DB12015 L01EM03 CHEMBL2396661 Advanced Metastatic Breast Cancer PIK3C3; PIK3R4; PIK3R3; MAP2K1; PIK3CA; ERBB2; PIK3R1; RB1; SGK1; HRAS; PIK3R5; PIK3R6; ESR1; BRAF; FGFR3; PIK3CG; PTEN; CDK4; PIK3CB; ARID1A; PIK3C2A; PIK3C2B; ESR2; PI4KA; FGFR1; NRAS; MTOR; FGFR2; PIK3CD; PIK3C2G; TP53; PIK3R2 2024-02-07 Altretamine N N Y N 1990 N DB00488 L01XX03 CHEMBL1455 Ovarian Cancer; Ovarian Cancer Stage III CYP1A2 2024-02-07 Aminolevulinic Acid Y Y N N 1999 N DB00855 L01XD04 CHEMBL601 Basal Cell Carcinoma (BCC); Squamous Cell Carcinoma (SCC) BCL2 2024-02-07 Amivantamab Y Y N N 2021 N DB16695 L01FX18 CHEMBL4297774 Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer EGFR; MET 2024-02-07 Amrubicin N N N Japan N 2002 DB06263 L01DB10 CHEMBL1186894 TOP2A 2024-02-07 Amsacrine N N N N 1987 N DB00276 L01XX01 CHEMBL43 Leukemia, Acute; Refractory Leukemia TOP2A; MTOR; ATXN2; CYP1A2; CYP2C19; CYP2C9; BTF3P11; ATAD5; CYP3A4; CYP2D6; HSD17B10; CBX1; DRD1; EHMT2; TOP2B 2024-02-07 Anastrozole N Y Y Y 1995 Y DB01217 L02BG03 CHEMBL1399 Advanced Breast Cancer; Early Breast Cancer; Locally Advanced Breast Cancer (LABC); Metastatic Breast Cancer; Invasive, early Breast Cancer CYP19A1; KMT2C; ESR1; ESR2; TNFSF11; PGR; TNFRSF11B; IGF2; ERBB2; CYP1B1; MAP4K4; TUBB1; DLG2; CSMD1 2024-02-07 Apalutamide Y Y N N 2018 N DB11901 L02BB05 CHEMBL3183409 Nonmetastatic Prostate Cancer AR 2024-02-07 Arsenic Trioxide Y Y N Y 2018 Y DB01169 L01XX27 CHEMBL1200978 Refractory Acute Promyelocytic Leukemia FAS; SERPINE1; TXNRD2; CCND1; CDKN1A; IKBKB; FLT3; TXNRD1; FGFR1; HSPA4; IL6; EPO; SMO; MYCN; TERT; MAPK3; RARA; BDNF; JUN; BIRC5; MT1A; MAPK1; MAPK10; PML; GSTO1; DNMT1 2024-02-07 Asciminib Y Y N N 2021 N DB12597 L01EA06 CHEMBL4208229 Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase ABL1 2024-02-07 Asparaginase Y Y N Y 1994 N DB00023 L01XX02 CHEMBL2108989 Acute Lymphoblastic Leukaemias (ALL) ETV6; GRIA1; NFATC2; GATA3; PNPLA3; CPA2; HLA-DRB1; MTHFR; LPL; PYGL; SOD2; ASNS 2024-02-07 Atezolizumab Y Y N N 2016 N DB11595 L01FF05 CHEMBL3707227 Metastatic Non-Small Cell Lung Cancer; Small Cell Lung Cancer (SCLC); Triple Negative Breast Cancer (TNBC); Urothelial carcinoma ureter metastatic; Locally advanced Urothelial Carcinoma BRAF; CD274; STK11; ALK; ARID1A; KRAS; JAK3; HLA-DRA; MDM4; EGFR; PBRM1; CTLA4; FGFR3; CX3CL1; PTEN 2024-02-07 Avapritinib Y Y N N 2020 N DB15233 L01EX18 CHEMBL4204794 Metastatic Gastrointestinal Stromal Tumor; Unresectable Gastrointestinal stromal tumor KIT; CBL; FLT3; PDGFRA 2024-02-07 Avelumab Y Y N N 2017 N DB11945 L01FF04 CHEMBL3833373 Locally advanced disease has progressed during or following platinum-containing chemotherapy urothelial carcinoma (UC); Locally advanced disease has progressed within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy urothelial carcinoma (UC); Metastatic Merkel Cell Carcinoma (MCC); Metastatic disease has progressed during or following platinum-containing chemotherapy urothelial carcinoma (UC); Metastatic disease has progressed within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy urothelial carcinoma (UC) CD274; MLH1; ATM; MSH6 2024-02-07 Axicabtagene Ciloleucel Y Y N N 2017 N DB13915 L01XX70 CHEMBL3989989 Refractory Diffuse large B-cell lymphoma NOS; Refractory High grade B-cell lymphoma Burkitt-like lymphoma; Refractory Primary Mediastinal Large B-Cell Lymphoma; Relapsed Diffuse large B-cell lymphoma NOS; Relapsed High grade B-cell lymphoma Burkitt-like lymphoma; Relapsed Primary Mediastinal Large B-Cell Lymphoma CD19 2024-02-07 Axitinib Y Y N N 2012 N DB06626 L01EK01 CHEMBL1289926 Advanced Thyroid cancer FLT1; PDGFRB; FLT4; KDR; YES1; BRAF; ABL1; PDGFB; VHL; UGT1A7; ABCG2; OR2B11; UGT1A10; UGT1A8; UGT1A9; HIF1A; KIT; PDGFRA 2024-02-07 Azacitidine Y Y N N 2004 Y DB00928 L01BC07 CHEMBL1489 Acute Myeloid Leukemia (AML); Chronic Myelomonocytic Leukemia TAGLN; ATAD5; IDH1; DNMT1; NFE2L2; TRIT1; SMAD3; TET2; GSTP1; TP53; CDA; AFP; RORC; GGT1; PLAU; ALDH1A1; GATA2; TG; IDH2; NR3C1; HBB; LIF; CD247; AR; ABL1; THPO; DNMT3A; IL11; HTT; MYC; GMNN; FLT3; MGMT 2024-02-07 BCG Vaccine Y Y N Y DB12768 L03AX03 CHEMBL2108905 Non-Invasive Bladder Urothelial Carcinoma; Recurrent Superficial Bladder Cancer; Urothelial Carcinoma Recurrent; Carcinoma in situ of urinary bladder CSF2; NOS1; SFTPA1; IL15; HLA-B; BAX; TNF; FAS; EIF2AK2; MAPK8; AFP; PIK3CA; CXCL2 2024-02-07 Belantamab Mafodotin Y Y N N 2020 N DB15719 L01FX15 CHEMBL4298209 Relapsed Or Refractory Multiple Myeloma TUBB2A; TUBB1; TUBA3C; TUBB3; TUBB2B; TUBB4A; TUBA1B; TUBB8; TNFRSF17; TUBB4B; TUBB; TUBA3E; TUBA1A; TUBB6; TUBA1C; TUBA4A 2024-02-07 Belinostat N Y N N 2014 N DB05015 L01XH04 CHEMBL408513 Relapsed Peripheral T-Cell Lymphoma; Refractory Peripheral T-cell Lymphoma Unspecified HDAC1; HDAC4; HDAC9; HDAC3; HDAC5; HDAC8; HDAC11; UGT1A1; FBXW7; HDAC2; HDAC6; KMT2A; HDAC10; HDAC7 2024-02-07 Belotecan N N N South Korea N 2003 DB12459 L01CE04 CHEMBL2111084 TOP1 2024-02-07 Belzutifan N Y N N 2023 N DB15463 L01XX74 CHEMBL4585668 Advanced Renal Cell Carcinoma VHL; EPAS1 2024-02-07 Bendamustine N Y Y Y 2008 Y DB06769 L01AA09 CHEMBL487253 Chronic Lymphocytic Leukaemia (CLL); Follicular Non-Hodgkin's Lymphoma Refractory; Refractory Hodgkin Lymphoma; Refractory Mantle Cell Lymphoma; Waldenstrom's Macroglobulinemia (WM); Recurrent multiple myeloma; Refractory indolent B cell non-hodgkin lymphoma CD69; ATM; TP53 2024-02-07 Bevacizumab Y Y N Y 2004 N DB00112 S01LA08; L01FG01 CHEMBL1201583 Cervical Cancer Metastatic; Metastatic Colorectal Cancer (MCRC); Metastatic Non-Squamous Non-Small Cell Lung Cancer; Metastatic Renal Cell Carcinoma; Persistent Cervical Cancer; Recurrent Cervical Cancer; Recurrent Glioblastoma; Stage III epithelial ovarian cancer following initial surgical resection; Stage IV epithelial ovarian cancer following initial surgical resection; Fallopian tube cancer following initial surgical resection; Locally advanced nonsquamous non-small cell lung cancer; Primary peritoneal cancer following initial surgical resection; Recurrent Non-Squamous Non-Small Cell Lung Cancer; Recurrent Platinum-Sensitive Epithelial Ovarian Cancer; Recurrent Platinum-resistant Epithelial Ovarian Cancer; Recurrent platinum drug resistant Fallopian tube cancer; Recurrent platinum drug resistant primary peritoneal cancer; Recurrent platinum sensitive primary peritoneal cancer; Recurrent platinum-sensitive fallopian tube cancer; Unresectable Non-Squamous Non-Small-Cell Lung Cancer EDN1; HRAS; NF1; VEGFA; CXCR4; KRAS; NF2; MTHFR; SHMT1; ANXA11; EGFR; CXCL8; KIT; HSP90AB1; ARID1A; MGAT4A; GC; VEGFB; CCT3; MMP9; ALK; PRKCA; TP53; THBS2; HOXC10; PIK3CA; F2R; EML4; VEGFC; FOXF1; MMP2; GGH; IDH1; BRAF; VHL; RALBP1 2024-02-07 Bexarotene Y Y N N 1999 Y DB00307 L01XF03 CHEMBL1023 Refractory peripheral cutaneous T-cell lymphoma RXRA; RXRB; MAPK8; KAT2A; RXRG; NR1I2; BLM; NR1H3; USP1 2024-02-07 Bicalutamide N Y Y Y 1995 Y DB01128 L02BB03 CHEMBL409 Stage D2 Prostatic carcinoma CYP2B6; FST; BAX; CFLAR; AR; KMT2D; VDR; KLK3; CDH1 2024-02-07 Binimetinib Y Y N N 2018 N DB11967 L01EE03 CHEMBL3187723 Metastatic Melanoma; Unresectable Melanoma MAP2K2; APC; PTEN; MAP2K1; KRAS; BRAF; UGT1A1; NRAS; JAK2; MAP2K3; HRAS; ATM; MAP2K5; MAP2K4; PIK3CA; MAP2K6; MAP2K7; NF1; KIT 2024-02-07 Bleomycin N Y Y Y 1973 Y DB00290 L01DC01 CHEMBL403664 Cervical Cancers; Head and Neck Carcinoma; Intracranial Germ Cell Tumors; Lymphoma, Hodgkins; Malignant Pleural Effusions; Non-Hodgkin's Lymphoma (NHL); Ovarian Cancer; Penile Cancer; Testicular Cancer; Vulvar Cancers; Early Kaposi's sarcoma IFNG; MAPK8; F2R; PLAU; NFE2L2; SMAD2; BLMH; AFP; WRN; GJA1; CCL17; CTLA4; GSTP1; ADK; GSTM1; BRCA1; LIG1 2024-02-07 Blinatumomab Y Y N N 2014 N DB09052 L01FX07 CHEMBL1742992 Precursor B-Lymphoblastic Lymphoma/Leukaemia Refractory; Relapsed B cell precursor Acute lymphoblastic leukemia CD19; CD3E; CD3D; ABL1; BCR; CD3G; CD247 2024-02-07 Bortezomib Y Y N Y 2003 Y DB00188 L01XG01 CHEMBL325041 Mantle Cell Lymphoma (MCL); Multiple Myeloma (MM) PSMB1; PSMD7; PSMC2; PSMA3; PSME1; PSMB4; PSMD4; PSMC1; PSMD12; PSMD3; BDNF; PSMA7; PSMD14; PSMD10; PSMB6; PSMD8; PRSS3; PSMA4; PSMB10; CAPN1; PSMD10P1; PSMC3; PSMB11; F2; PSME4; PSMD1; PSME2; PSMD9; PSMB2; PSMD13; PLG; PSMB8; PSME2P2; PIPSL; PSMA5; PMAIP1; PSMA2; PSMC4; CTSB; PLAT; F12; ADRM1; PSMB3; PSMC5; PRSS1; AR; PSMF1; PSMA8; CTLA4; XIAP; PSMC3IP; PSME3; BCL2; BCL2L2; PSMD5; CTSL; PSMC1P1; NFE2L2; CCND1; SEM1; PSMB9; PSMD11; FLT3; PSMA1; E2F1; DDIT3; PSMD10P3; PIK3CA; TP53; PRB2; PRSS2; HSPB2; FGFR3; PIK3CG; GATA2; PSMD10P2; PSMD6; NFKB1; PSMC6; PSMD4P1; PSMD2; PSMB7; HSPA4; PSMA6; PSMB5 2024-02-07 Bosutinib Y Y N N 2010 N DB06616 L01EA04 CHEMBL288441 Refractory, accelerated phase Chronic myelogenous leukemia; Refractory, blast phase Chronic myelogenous leukemia; Refractory, chronic phase Chronic myelogenous leukemia ABL1; SRC; BRCA2; LYN; CAMK2G; HCK; BRAF; BCR 2024-02-07 Brentuximab vedotin Y Y N N 2011 N DB08870 L01FX05 CHEMBL1742994 B-large cell anaplastic Lymphoma (Kiel Classification) refractory; Refractory Hodgkin Lymphoma; Post-autologous hematopoietic stem cell transplantation Hodgkin lymphoma TUBB2A; TUBA3C; TUBA4A; TUBB1; ALK; TNFRSF8; TUBB2B; TUBB4A; TUBA1A; TUBB; TUBB4B; TUBA1B; TUBB6; TUBA3E; TUBB8; TUBB3; TUBA1C 2024-02-07 Brexucabtagene Autoleucel Y Y N N 2020 N DB15699 L01XL06 CHEMBL4594618 Refractory Mantle Cell Lymphoma; Relapsed Mantle Cell Lymphoma CD19 2024-02-07 Brigatinib Y Y N N 2017 N DB12267 L01ED04 CHEMBL3545311 Metastatic Non-Small Cell Lung Cancer ALK; EGFR; FGFR1; ROS1; FLT3; TP53; EML4 2024-02-07 Buserelin N N Y N 2017 N DB06719 L02AE01 CHEMBL2110824 Stage D2 Prostatic carcinoma GNRHR; IGFBP1 2024-02-07 Busulfan Y Y N N 1954 Y DB01008 L01AB01 CHEMBL820 Essential Thrombocythemia (ET); Polycythemia Vera (PV); Chronic Chronic myelogenous leukemia GSTM1; GSTA1; BCR; ABL1; CYP2D6; CYP2C9; ADK; GSTP1; ITGAL; CYP2C19; CYP2B6; THPO; CYP3A4; SHBG; GALC; G6PD; CYP1A2; ABCC3 2024-02-07 Cabazitaxel Y Y N N 2010 N DB06772 L01CD04 CHEMBL1201748 Refractory, metastatic hormone-refractory Prostate cancer TUBA1C; TUBB2B; TUBA3C; TUB; IGF2; TUBB4B; TUBA1A; CYP3A4; TUBA4A; TUBB; TUBB1; TUBA1B; TUBB3; TUBB8; TUBB2A; TUBA3E; CYP3A5; ABCB1; TUBB6; TUBB4A 2024-02-07 Cabozantinib Y Y N N 2012 N DB08875 L01EX07 CHEMBL2105717 Advanced Renal Cell Carcinoma; Hepatocellular Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Progressive, metastatic Medullary thyroid cancer MET; RET; KIT; PIK3CA; HRAS; HGF; TEK; FLT3; CTNNB1; ABL1; GNA11; KDR; NRAS; CFLAR; YES1; ROS1 2024-02-07 Calaspargase Pegol N Y N N 2018 N DB14730 CHEMBL2108728 Acute Lymphoblastic Leukaemias (ALL) ASRGL1 2024-02-07 Capecitabine Y Y N Y 1998 Y DB01101 L01BC06 CHEMBL1773 Duke's C Colon cancer; Esophageal Cancers; Hepatobiliary Cancers; Malignant Neoplasm of Stomach; Metastatic Breast Cancer; Metastatic Colorectal Carcinoma; Pancreatic Cancer Metastatic; Refractory Fallopian Tube Carcinoma; Metastatic pancreatic endocrine carcinoma; Refractory Ovarian cancer; Refractory peritoneal cancer; Refractory, metastatic Colorectal carcinoma SSU72; CYP1A1; NSUN3; ABCG2; DPYD; TP53; REV3L; CES1P1; ADCY2; KRAS; SLC19A1; ABCB1; TYMS; PIK3CA; AREG; CES1; MGAT4A; UGT1A1; CD96; EXO1; ATM; BRAF; PTEN; TYMSOS; UPB1; ADGRG7; SELE; UMPS; CYP19A1; ZMIZ1; SLC22A7; DLG5; ERBB2; PTGS2 2024-02-07 Capivasertib N Y N N 2023 N DB12218 L01EX27 CHEMBL2325741 Hormone Receptor-positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer AKT2; PIK3CA; AKT1; AKT3; PTEN; MTOR; TP53 2024-02-07 Capmatinib Y Y N N 2020 N DB11791 L01EX17 CHEMBL3188267 Metastatic Non-Small Cell Lung Cancer MET; PTEN 2024-02-07 Carboplatin N Y Y Y 1989 Y DB00958 L01XA02 CHEMBL1351 Advanced Cervical Cancer; Advanced Endometrial Cancer; Advanced Esophageal Cancers; Advanced Head and Neck Cancer; Advanced Melanoma; Advanced Non Small Cell Lung Cancer; Advanced Ovarian Carcinoma; Advanced Sarcoma; Metastatic Breast Cancer; Neuroendocrine Carcinoma of the Skin; Pleural mesothelioma malignant; Refractory Hodgkin Lymphoma; Retinoblastoma; Advanced Bladder cancer; Advanced Small cell lung cancer; Advanced Testicular cancer; Advanced Thymoma; Advanced thymic carcinoma; Refractory Non-Hodgkin's lymphoma SERPINA5; SLC31A1; KRAS; MAP3K1; ATP7B; GCLC; DSCAM; MUCL3; HSD17B10; CYP3A5; CDSN; EGFR; GSTP1; MTR; NF2; PSORS1C1; C6orf15; ATP7A; CDKN1A; XRCC1; HCP5; MAD1L1; ACSS2; VDR; VEGFA; PTEN; TP53; TP73; ATAT1; FGFR1; SLC19A1; SLCO1B3; PIK3CA; ERBB2; DOCK8; ETS2; ERCC2; ROS1; GSTT1; NRAS; GPX5; NR1I2; BRCA1; USP1; MTHFR; ABCB1; PPP1R18; FNTB; RRM1; POLK; UGT1A1; BIRC5; HLA-C; CDK2; TNF; ERCC1; ERBB3; TRIM5; KAT2A; APEX1; RNF8; ALDH1A1; OPRM1; EIF4E2; ADAMTSL4-AS1; MAPT; BCL2; BRCA2; SOX10; SERPINC1; GSR; PRRC2A; NRG1; TIGD1; MSH5; RAF1; XYLT2; DDX53; SCN10A; OR4D6 2024-02-07 Carfilzomib Y Y N N 2009 N DB08889 L01XG02 CHEMBL451887 Refractory Multiple Myeloma; Waldenstrom's Macroglobulinemia (WM) PSMD8; PSMA4; PSMD13; PSMB7; PSMB1; PSMB10; PSMC2; PSMB9; PSMA2; PSMA6; PSMC4; NFE2L2; PSMD4; PSMB6; PSMB3; PSMB4; PSMB8; PRB2; PSMC5; PSMD6; PSMB5; PSMD7; PSMA7; PSMD12; PSMA1; PSMA5; PSMD14; PSMB11; PSME4; PSMC6; PIPSL; AR; PSMD2; PSMD10P1; PSMF1; PSMA3; PSMD3; PSMD10; PSMD9; PSMD5; SEM1; PSMC3; PSMD4P1; PSMD10P2; PSMC3IP; VEGFA; PSME1; PSMD10P3; PSME2P2; ADRM1; PSMD1; PSME3; PSMC1; PSMA8; PSMB2; PSME2; PSMC1P1; PSMD11; KDR 2024-02-07 Carmofur N N N Japan N DB09010 L01BC04 CHEMBL460499 CYP3A4 2024-02-07 Carmustine Y Y N N 1977 Y DB00262 L01AD01 CHEMBL513 Astrocytomas; Brain Stem Gliomas; Ependymomas; Glioblastomas; Medulloblastomas; Mycosis Fungoides (MF); Recurrent Glioblastoma Multiforme; Refractory Hodgkin Lymphoma; Refractory Multiple Myeloma; Tumors Metastatic to Brain; High grade newly diagnosed Glioma; Refractory Non-Hodgkin's lymphoma CYP2C9; CYP2D6; CYP3A4; MGMT; GSR; G6PD; PLAU; E2F1; CYP2C19; CYP1A2; ALDH1A1 2024-02-07 Cemiplimab Y Y N N 2018 N DB14707 L01FF06 CHEMBL4297723 Metastatic cutaneous squamous cell carcinoma; Locally advanced cutaneous squamous cell carcinoma, and not a candidate for curative surgery or curative radiation PDCD1; CD274; ROS1; CDK12; ALK; EGFR 2024-02-07 Ceritinib Y Y N N 2014 N DB09063 L01ED02 CHEMBL2403108 Refractory, locally advanced Non-small cell lung cancer; Refractory, metastatic Non small cell lung cancer EML4; ALK; ABCB1; NRAS; INSR; IGF1R; NPM1; TP53; TSSK1B; MAP2K1; CYP3A4; ROS1 2024-02-07 Cetuximab Y Y N N 2004 N DB00002 L01FE01 CHEMBL1201577 Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN); Metastatic Colorectal Cancer (MCRC); Metastatic Squamous Cell Carcinoma of the Head and Neck; Recurrent Squamous Cell Carcinoma of the Head or Neck; Regionally Advanced Squamous Cell Carcinoma of the Head and Neck PTEN; EGFR; KRAS; MAP2K1; HBEGF; NT5E; ERBB3; TGFA; GC; NRAS; PIK3CA; FCGR3A; EREG; NF2; IDH1; HRAS; BAX; EGF; BRAF; CXCL8; NRG3; MGAT4A; SMAD4; NRG2; MET; AREG; CTNNB1; PTP4A3; BTC; TP53; BDNF; ERBB2; VPS37A; NRG1 2024-02-07 Chlorambucil N Y Y Y 1957 N DB00291 L01AA02 CHEMBL515 Chronic Lymphocytic Leukaemia (CLL); Hodgkins Disease (HD); Non-Hodgkin's Lymphoma (NHL); Waldenstrom's Macroglobulinemia (WM); Giant follicular lymphoma CXCL12; BAZ2B; NFKB1; ERBB2; RORC; MGMT; PALB2; GFER; GSTM1; TP53; FANCC 2024-02-07 Ciltacabtagene Autoleucel Y Y N N 2022 N DB16738 CHEMBL4802263 Refractory Multiple Myeloma, Relapsed Multiple Myeloma TNFRSF17 2024-02-07 Cisplatin N Y Y Y 1978 Y DB00515 L01XA01 CHEMBL2068237 Advanced Pancreatic Cancer; Breast Cancer; Cervical Cancers; Esophageal Cancers; Head and Neck Carcinoma; Hepatobiliary Cancers; Hepatoblastomas; Malignant Neoplasm of Stomach; Medulloblastomas; Metastatic Melanoma; Multiple Myeloma (MM); Neuroblastomas; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer Metastatic; Pleural Mesotheliomas; Primary Central Nervous System Lymphoma (PCNSL); Recurrent Endometrial Cancer; Refractory Hodgkin Lymphoma; Sarcoma, Osteogenic; Small Cell Lung Cancer (SCLC); Thymic Cancer; Advanced Bladder cancer; Metastatic Anal cancer; Metastatic Endometrial cancer; Metastatic Penile cancer; Metastatic Testicular cancer; Refractory Non-Hodgkin's lymphoma BARD1; KRAS; TP73; BLMH; NR1I2; MIR21; ATR; GABPA; BIRC7; BAX; CYBA; MTHFD1; ESR1; APEX1; G6PD; GSTT1; SLC19A1; ACYP2; KDM4E; RECQL; ATP7B; MTR; MAPT; SLC22A1; ADH1C; TP53; POLR1G; GALNT18; LIF; ALK; FGFR1; FAS; BCL2; HEXB; ERCC6; RRM1; MGMT; GSTP1; NRG1; HMGB1; IL6; NFE2L2; TGM2; ALOX15; IFNG; PPP1R13L; ATM; SLC31A1; OTOS; BRCA2; KAT2A; PALB2; CASP3; RB1; EHMT2; ACTL6A; H2AC25; HTR4; TPMT; IDH1; DNMT1; XRCC3; CGA; ABCC4; NTRK2; MT1H; PLAU; GALNT14; PTEN; BIRC5; HPGD; RGS4; FANCC; RAD51C; PIK3CA; ABCC1; CBX1; TERC; FASLG; MTHFR; CCND1; CDC25C; HSD17B10; GCLC; FANCA; CLCN6; LRP2; FXN; STAT1; GADD45A; HSPA8; PRL; ABCC5; RARS1; HSPA4; XRCC5; MLLT3; TOP1; XPC; DRAM1; ALDH1A1; MUTYH; DFFB; TMEM43; GRP; ATRX; ACSS2; E2F1; KRT20; AQP9; MYCN; NRAS; SMARCA4; OSGEP; MDH2; GCLM; AURKA; CHEK1; ANPEP; GSTM4; ERCC4; GNAS; CDK12; NF2; TYMS; GPX5; MYC; UBE2I; CSNK2A3; MT1F; BRCA1; MECP2; RAF1; XIAP; MAP3K1; CDH17; XRCC1; EGFR; ERCC2; MSH2; DCBLD1; CXCR4; ERCC1; CD44; MDM2; PPARD; DDIT3; MPHOSPH8; FGFR3 2024-02-07 Cladribine Y Y N N 1993 Y DB00242 L04AA40; L01BB04 CHEMBL1619 Chronic Lymphocytic Leukaemia (CLL); Cutaneous T-Cell Lymphoma (CTCL); Hairy Cell Leukemia (HCL); Non-Hodgkin's Lymphoma (NHL) RRM2B; CDKN1A; DCK; NFE2L2; TGFB1; BCL2L2; RRM2; YES1; NT5C1A; TP53; ADA; DIABLO; RRM1; XIAP; IL2RA 2024-02-07 Clofarabine Y Y N N 2004 Y DB00631 L01BB06 CHEMBL1750 Acute Lymphoblastic Leukaemia Recurrent; Refractory Acute Lymphoblastic Leukemia; Refractory Acute Myelogenous Leukemia (AML); Refractory Langerhans cell histiocytosis POLA1; RRM1; POLE2; RRM2; POLE3; POLA2; AR; POLD2; POLD4; FLT3; POLE; POLD3; PRIM1; APBB1; POLD1; RRM2B; PRIM2 2024-02-07 Cobimetinib Y Y N N 2015 N DB05239 L01EE02 CHEMBL2146883 Metastatic Melanoma; Unresectable Melanoma KRAS; MAP2K2; NRAS; BRAF; NF1; MAP2K3; ARAF; MAP2K1; RAF1; CDKN2A; PIK3CA; MAP2K5; MAP2K4; MAP2K6; MAP2K7; CBL 2024-02-07 Copanlisib N Y N N 2017 N DB12483 L01EM02 CHEMBL3218576 Relapsed Follicular Lymphoma PIK3CG; PIK3CA; PIK3CD; PIK3R3; PIK3R6; NRAS; AURKB; PIK3R4; PIK3C2G; PIK3CB; PIK3C3; PIK3R1; PIK3R2; PIK3R5; KIT; PIK3C2B; PIK3C2A; PTEN 2024-02-07 Crizotinib Y Y N N 2011 N DB08865 L01ED01 CHEMBL601719 Metastatic Non-Small Cell Lung Cancer ABL1; IGF1R; TP53; BRAF; MET; ALK; NPM1; EML4; ROS1; NTRK2; EGFR; KIT; PIK3CA; ABCB1; ERBB2; HRAS; NTRK1; PTPN12; NTRK3; KRAS; JAK2; AREG 2024-02-07 Cyclophosphamide N Y Y Y 1959 Y DB00531 L01AA01 CHEMBL88 Acute Lymphoblastic Leukaemias (ALL); Acute Myelocytic Leukemia; Adenocarcinoma of the Ovaries; Breast Cancer; Burkitt's Lymphoma; Chronic Lymphocytic Leukaemia (CLL); Chronic Myeloid Leukemia (CML); Disseminated Neuroblastoma; Ewing's Sarcoma; Lung Cancers; Lymphoma, Hodgkins; Multiple Myeloma (MM); Non-Hodgkin's Lymphoma (NHL); Ovarian germ cell tumour; Pheochromocytomas; Retinoblastoma; Rhabdomyosarcomas; Waldenstrom's Macroglobulinemia (WM); Advanced Alibert-Bazin syndrome; Histiocytic lymphoma; Metastatic gestational trophoblastic tumor; Mixed-cell type lymphoma; Refractory Small cell lung cancer; Relapsed Wilm's tumor EHMT2 2024-02-07 Cytarabine Y Y N Y 1969 Y DB00987 L01BC01 CHEMBL803 Acute Lymphocytic Leukemia (ALL); Acute Myeloid Leukemia (AML); Acute Promyelocytic Leukemia (APL); Leptomeningeal Metastases; Meningeal leukemia; Non-Hodgkin's Lymphoma (NHL); Blast phase Chronic myelocytic leukemia POLB; CYP2C9; GSTP1; FLT3; DOK5; NT5C2; RRM1; IDH2; CDA; NOS3; CSF2; SLCO1B1; CCND1; CYP2E1; VDR; POLD2; FCGR3A; BMP7; RRM2B; POLD1; POLA1; PRIM2; SLC22A12; NTRK1; SLC29A1; LINC00251; P2RY12; ABCC4; IDH1; DCK; ALK; CYP1A2; ITGAV; NCOA3; GATA3; IKZF1; KIT; GSTM1; CYP3A4; POLE2; CYP2C19; POLD4; TP53; IL1B; RRM2; CYP2D6; POLE3; BIRC5; POLE; POLD3; NT5C3A; NRAS; SULT2B1; XIAP; HSPA4; MED12L; ADH1A; ABCC3; RUNX1; FCGR3B; PRIM1; TP73; WT1; MAGEA1; EHMT2; POLA2; KMT2A; NRG1 2024-02-07 Dabrafenib Y Y N N 2013 N DB08912 L01EC02 CHEMBL2028663 Metastatic Melanoma; Unresectable Melanoma; Metastatic Non-small cell lung cancer with a BRAF V600E mutation; Pediatric low-grade glioma (LGG) with a BRAF V600E mutation; Locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation RAC1; MAP2K6; NRAS; CDKN2A; MAP2K1; ALK; PTEN; MAP2K2; PIK3CA; MAP2K5; HRAS; MAP2K7; MAP2K3; MAP2K4; ATXN1L; AKT1; HLA-DRB1; NF1; G6PD; TP53; MITF; EZH2; EML4; KRAS; BRAF 2024-02-07 Dacarbazine N Y Y Y 1975 Y DB00851 L01AX04 CHEMBL476 Advanced Soft Tissue Sarcoma; Lymphoma, Hodgkins; Metastatic Melanoma; Pheochromocytomas; Advanced Medullary thyroid cancer; Advanced Pancreatic neuroendocrine tumor FN1; PLAU; POLA2; CYP2D6; CYP1A2; ADK; BAX; EPM2AIP1; CYP2C19; CYP3A4; CXCL8; CYP2C9; GSTM1; MGMT 2024-02-07 Dacomitinib Y Y N N 2018 N DB11963 L01EB07 CHEMBL2110732 Metastatic Non-Small Cell Lung Cancer EGFR; ERBB4; ERBB3; ERBB2 2024-02-07 Dactinomycin N Y N Y 1964 Y DB00970 L01DA01 CHEMBL1554 Ewing's Sarcoma; Ovarian Cancer; Rhabdomyosarcomas; Sarcoma, Osteogenic; Wilms' tumor; Metastatic nonseminomatous Testicular cancer MTR; TFPI; BDNF; HTT; APEX1; BGLAP; RECQL; VDR; MTHFR; CD5; AR; THRB; TOP2A; BIRC5; CYP1A2; CYP3A4; ESR1; NR3C1; CEL; RXRA; COIL; TNFRSF1B; CYP2D6; CSF1; ALOX15; NRG1; PPARD; GRB2; AFP; PIK3CB; RORC; EHMT2; DDIT3; NTF3; TNFRSF8 2024-02-07 Daratumumab Y Y N N 2015 N DB09331 L01FC01 CHEMBL1743007 Multiple Myeloma (MM); Refractory Multiple Myeloma; Relapsed Multiple Myeloma; Relapsed Or Refractory Multiple Myeloma CD38 2024-02-07 Daratumumab, Hyaluronidase N Y N N 2020 N DB09331 L01FC01 CHEMBL1743007 Multiple Myeloma (MM); Refractory Multiple Myeloma; Relapsed Multiple Myeloma; Relapsed Or Refractory Multiple Myeloma CD38 2024-02-07 Darolutamide Y Y N N 2019 N DB12941 L02BB06 CHEMBL4297185 Non-mestatatic castrate-resistant prostate cancer AR 2024-02-07 Dasatinib Y Y N Y 2006 Y DB01254 L01EA02 CHEMBL1421 Acute Lymphoblastic Leukaemias (ALL); Chronic Myeloid Leukemia (CML) ABL1; HRAS; MAP2K2; ABL2; EPHA2; KIT; LCK; PDGFRA; SRC; ARID1A; FYN; CBL; JAK2; KRAS; PDGFRB; MAP4K5; ABI1; YES1; ERBB4; IDH2; BTK; BCR; CSF3R; FGR; APC; TET2; LIMK1; LYN; DYRK3; FGFR1; MAPK14; BRAF; AR; ACVR1; TEC; FRK; SYK; GMNN; SRMS; IDH1; PKN2; ABCB1; HCK; MAP3K20; AXL; CDC42BPA; ABCG2; BLK; PPARD; AURKB; SMAD3; BRCA2; CSF1R; SIK2; SLK; NF1; MINK1; MAP3K10; ERBB2; FES; KDR; PTK6; CRKL; PLK4; MAP2K1; IRAK4; STAT5B; FGFR3; TNK2; DDR2; TAOK1 2024-02-07 Daunorubicin N Y Y Y 1979 Y DB00694 L01DB02 CHEMBL178 Acute Lymphocytic Leukemia (ALL); Acute Myeloid Leukemia (AML); Acute Myeloid Leukemia With Myelodysplasia-Related Changes; Acute erythroid leukemia; Acute monocytic leukaemia; Newly diagnosed Therapy-Related Acute Myeloid Leukemia IDH1; SETD4; THRB; FLT3; SZRD1; SLC28A3; RECQL; MAN1B1; LINC00251; TOP2A; NPM1; HDAC2; BMP7; DCK; WT1; HDAC6; HDAC3; AKR1C4; ABCG2; RUNX1; DNMT3A; BLM; KDM4E; APP; TYMS; UGT1A6; HDAC10; ABCC1; HDAC9; HDAC7; ATP7B; PNPLA3; HDAC8; ANXA5; GSTP1; IKZF1; GATA3; CYP1A1; CBR1; FAS; CBR3; DOK5; MAPT; NOS3; TOP1; USP1; RARG; CDK2; CBFB; POLK; IDH2; MTHFR; NRP2; APEX1; SLCO1B1; KMT2A; AR; HDAC4; HDAC5; HTT; EHMT2; HDAC11; FMO3; AKR7A2; TOP2B; HDAC1; ABCB1; RPSA; AKR1C3 2024-02-07 Daunorubicin, Cytarabine Liposome Y Y N N 2017 Y DB00694 L01XY01; L01DB02 Acute Lymphocytic Leukemia (ALL); Acute Myeloid Leukemia (AML); Acute Myeloid Leukemia With Myelodysplasia-Related Changes; Acute erythroid leukemia; Acute monocytic leukaemia; Newly diagnosed Therapy-Related Acute Myeloid Leukemia 2021-10-28 Decitabine Y Y N N 2006 Y DB01262 L01BC08 CHEMBL1201129 Chronic Myelomonocytic Leukemia; Myelodysplastic Syndromes (MDS) DNMT1; TP53; IDH1; CCND2; CR2; CDKN2D; LIF; KRAS; DNMT3A; GSTP1; GMNN; THBS1; CTAG1B; IDH2; FLT3; IL2RA; TGM2; NR5A1; CYP27B1; APC; MUC2; MAGEA1 2024-02-07 Decitabine , Cedazuridine Y Y N N 2020 N Not found in DrugBank L01BC58 Acute Myeloid Leukaemia 2023-08-01 Degarelix Y Y N N 2008 N DB06699 L02BX02 CHEMBL415606 Advanced Prostate Cancer GNRHR; GNRHR2 2024-02-07 Denileukin Diftitox N Y N N 1999 N DB00004 L01XX29 CHEMBL1201550 Cutaneous T-Cell Lymphoma (CTCL) IL2RA; IL12RB1; IL12RB2; IL2RB; IL2RG; EEF2 2024-02-07 Denosumab Y Y N N 2010 N DB06643 M05BX04 CHEMBL1237023 Giant cell tumor of the bone; Refractory Hypercalcemia of malignancy TNFSF11; BRAF; TNFRSF11A 2024-02-07 Dexamethasone Y Y N Y 1958 Y DB01234 S03BA01; S02BA06; S01CB01; S01BA01; R01AD03; H02AB02; D10AA03; D07XB05; D07AB19; C05AA09; A01AC02 CHEMBL384467 Leukemia, Acute; Malignant Lymphomas; Multiple Myeloma (MM); Mycosis Fungoides (MF) AR; HTR7; PYGL; NR3C1; RPS19; SFTPA1; NPPC; DOK5; CYP2C9; FOLR1; RARA; AGTR1; SI; CHKA; BIRC5; SMAD3; KDR; SOAT1; ANXA1; HYAL2; GATA3; THRSP; IRS2; LINC00251; NR1I2; CTLA4; HSPA8; CHAT; CDK4; F9; SDS; CDK2; TEAD1; VEGFA; TGFBR3; ALK; GLS; GSTP1; TDO2; CARTPT; S100A10; TG; NFE2L2; VCAM1; SAG; APOB; UBR1; NRG1; DPEP1; CCL17; GGT1; TJP1; UGT1A1; CD86; TYMS; MT1F; VDR; KRT19; CYP3A4; CYP1A2; SERPINE1; PTGDR; PTH1R; CTNNB1; FABP1; SLC2A4; CHRM3; CRISPLD2; RET; CDK6; RELA; CDH17; TSC22D3; IGFBP1; NR5A1; CYP2C19; NTRK1; JUNB; CYP2D6; JAK3; BMP7; ACTC1; LIF; PZP 2024-02-07 Dexrazoxane Y Y N N 1995 Y DB00380 V03AF02 CHEMBL1738 TOP2B; TOP2A; CP; DPYS; MAPK8 2024-02-07 Diethylstilbestrol N N Y N 1973 N DB00255 G03CC05; G03CB02; L02AA01 CHEMBL411 ESR1; NPPC; HRAS; ESRRB; WNT7A; RORC; BDNF; TP53; AR; CYP2C19; ERBB2; NFE2L2; AMH; MYC; SLC5A7; CP; NR1I2; NR1H4; DNMT1; LPO; CYP2C9; BCL2; PTGES3; CYP3A4; CYP1A2; E2F1; GMNN; CYP2D6; ESRRG 2024-02-07 Dinutuximab Y Y N N 2015 N DB09077 L01XC16 CHEMBL3137342 High Risk Neuroblastoma MYCN 2024-02-07 Docetaxel Y Y N Y 1996 Y DB01248 L01CD02 CHEMBL92 Esophageal Cancers; Ewing's Sarcoma; Locally Advanced Breast Cancer (LABC); Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Hormone Refractory Prostate Cancer; Node Positive Breast Cancer; Ovarian Cancer Metastatic; Small Cell Lung Cancer (SCLC); Soft Tissue Sarcoma (STS); Advanced untreated gastric adenocarcinoma; Locally advanced Squamous cell carcinoma of head and neck; Locally advanced untreated non small cell lung cancer; Metastatic Squamous cell carcinoma of head and neck; Metastatic untreated non small cell lung cancer; Refractory, locally advanced Non small cell lung cancer; Refractory, metastatic Non small cell lung cancer TUBB3; TP53; RXRA; TUBB2B; BCL2; STK11; ESR1; VAC14; TUBB8; ERBB3; TUBB1; RAF1; FGFR1; EPHX1; ADAMTSL4-AS1; PGR; CHST3; SOX10; SLCO1B1; PPARD; XRCC3; BRD4; AKR1C3; SULT1C4; ACSS2; ABCC6; SPG7; FOLH1; HNF4A; XRCC1; PGP; TUBB6; ESR2; TUBB; CASP7; ERBB2; CD44; MUC16; CYP2A6; TUBA1C; NR1I3; CYP1A1; TUBB4B; ABCC1; PIK3CA; TUBB4A; GSTM1; SNORD68; TUB; KRAS; SLC10A2; TUBA3C; PPCDC; NR1I2; MDM4; TLE3; DDIT3; TUBB2A; RPL13; OPRM1; PRDX4; CYP3A5; BAX; ORM2; GSTP1; KLK3; RNF8; GAS6; MTHFR; PTEN; CYP4B1; HRAS; MAP3K1; XRCC4; BIRC5; FGFR3; IGF2; FBXW7; TUBA3E; TUBA1B; TUBA4A; NAT2; ABCG2; ATP7A; TUBA1A 2024-02-07 Dostarlimab Y Y N N 2021 N DB15627 L01FF07 CHEMBL4298124 Adults with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen MSH6; PDCD1; MLH1 2024-02-07 Doxorubicin N Y Y Y 1974 Y DB00997 L01DB01 CHEMBL53463 Acute Lymphoblastic Leukaemias (ALL); Acute Myeloblastic Leukemia; Advanced Endometrial Cancer; Advanced Soft Tissue Sarcoma; Bladder transitional cell carcinoma; Carcinoma, Bronchogenic; Gastric Carcinoma; Kaposi's Sarcoma AIDS Related; Lymphoma, Hodgkins; Malignant Lymphomas; Metastatic Breast Cancer; Multiple Myeloma (MM); Mycosis Fungoides (MF); Neuroblastomas; Ovarian Cancer Metastatic; Ovarian Carcinoma; Sarcoma, Bone; Sezary Syndrome; Soft Tissue Sarcoma (STS); Thyroid Carcinoma; Waldenstrom's Macroglobulinemia (WM); Wilms' tumor; Advanced Thymoma; Advanced uterine sarcoma TOP2A 2024-02-07 Doxorubicin Liposome Y Y N N 1998 Y Not found in DrugBank L01DB01 CHEMBL53463 Acute Lymphoblastic Leukaemias (ALL); Acute Myeloblastic Leukemia; Advanced Endometrial Cancer; Advanced Soft Tissue Sarcoma; Bladder transitional cell carcinoma; Carcinoma, Bronchogenic; Gastric Carcinoma; Kaposi's Sarcoma AIDS Related; Lymphoma, Hodgkins; Malignant Lymphomas; Metastatic Breast Cancer; Multiple Myeloma (MM); Mycosis Fungoides (MF); Neuroblastomas; Ovarian Cancer Metastatic; Ovarian Carcinoma; Sarcoma, Bone; Sezary Syndrome; Soft Tissue Sarcoma (STS); Thyroid Carcinoma; Waldenstrom's Macroglobulinemia (WM); Wilms' tumor; Advanced Thymoma; Advanced uterine sarcoma TOP2A 2024-02-07 Durvalumab Y Y N N 2017 N DB11714 L01FF03 CHEMBL3301587 Unresectable Stage III Non-small Cell Lung Cancer; Urothelial carcinoma ureter metastatic; Locally advanced Urothelial Carcinoma; Unresectable, locally advanced PD-L1 positive Lung Cancer Non-Small Cell Cancer (NSCLC) CD274; PBRM1; MLH1; ALK; ATM; IDH1; MSH2; MSH6 2024-02-07 Duvelisib Y Y N N 2018 N DB11952 L01EM04 CHEMBL3039502 Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL); Relapsed or Refractory Follicular Lymphoma; Refractory, relapsed small lymphocytic lymphoma TP53; PIK3CD; PIK3CG 2024-02-07 Edotreotide Y N N N 2019 N DB15494 V09IX09 CHEMBL408350 Neuroendocrine Tumors 2022-06-22 Eflornithine N Y N N 2023 N DB06243 L01XX79 CHEMBL830 High Risk Neuroblastoma TGM2; NR5A1; SMOX; XIAP; EHMT2; JUN; MTAP; PRL; KCNA1; ATF2; PLA2G2A; ODC1; ARG2; APC 2024-02-07 Elacestrant Y Y N N 2023 N DB06374 L02BA04 CHEMBL4297509 Advanced Breast Cancer, Metastatic Breast Cancer ESR1 2024-02-07 Elotuzumab Y Y N N 2015 N DB06317 L01FX08 CHEMBL1743010 Refractory Multiple Myeloma SLAMF7 2024-02-07 Elranatamab Y Y N N 2023 N DB15395 L01FX32 CHEMBL4297809 Relapsed or Refractory Multiple Myeloma TNFRSF17; CD3E; CD3D; CD3G 2024-02-07 Emapalumab N Y N N 2018 N DB14724 L04AA39 CHEMBL3989977 UNC13D; STX11; IFNG; RAB27A; SH2D1A; STXBP2; XIAP; PRF1 2024-02-07 Enasidenib N Y N N 2017 N DB13874 L01XX59 CHEMBL3989908 Refractory Acute Myelogenous Leukemia (AML); Relapsed Acute Myelogenous Leukemia (AML) FLT3; IDH1; IDH2 2024-02-07 Encorafenib Y Y N N 2018 N DB11718 L01EC03 CHEMBL3301612 Metastatic Melanoma; Unresectable Melanoma BRAF; RAF1; PTEN; KRAS; TP53; ARAF; MAP2K1; HRAS; NRAS 2024-02-07 Enfortumab Vedotin Y Y N N 2021 N DB13007 L01FX13 CHEMBL3301589 Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer NECTIN4 2024-02-07 Entrectinib Y Y N N 2019 N DB11986 L01EX14 CHEMBL1983268 Metastatic Solid Tumors; Non-Small Cell Lung Carcinoma (NSCLC); Tumors, Solid BTK; PLK4; FER; AURKB; NTRK1; STK3; SLK; CLK4; ROS1; ALK; PRKCG; NTRK3; LYN; NTRK2; MET; TNK2; PKN2; LCK; JAK3; CSF1R; BLK; AURKA; TBK1; FLT4; PRKAA1; MST1R; RPS6KA3; KIT; ABL1; GRK5; SYK; CLK2; CDK7; HIPK2; FRK; TAOK1; EML4; KDR; IGF1R; MAP4K5; FLT1; FGFR1; LTK; PRKCQ; FGFR3; SRC; MAP4K2; FYN; FLT3; MAP4K4; LRRK2; AXL; RET; CAMK1D; PTK2; DAPK3; JAK2 2024-02-07 Enzalutamide Y Y N N 2012 N DB08899 L02BB04 CHEMBL1082407 Metastatic Castration Resistant Prostate Cancer AR; PTEN; CYP17A1; PIK3CA; BRAF; CDK12; APC; TP53 2024-02-07 Epcoritamab Y Y N N 2023 N DB16672 L01FX27 CHEMBL4650393 Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-cell Lymphoma (DLBCL) CD3G; MS4A1; CD3D; CD3E 2024-02-07 Epirubicin N Y Y N 1999 Y DB00445 L01DB03 CHEMBL417 Breast Cancer; Breast Cancer Stage II; Breast Cancer Stage III; Colorectal Cancers; Hormone Refractory Prostate Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Papillary transitional cell carcinoma of bladder; Recurrent Superficial Bladder Cancer; Small Cell Lung Cancer (SCLC); Soft Tissue Sarcoma (STS); Stomach Tumor; Carcinoma in situ of urinary bladder PPP2R5D; RBX1; CYP2C8; FOXO1; PIK3R2; BIRC5; TP53AIP1; BCL2; SPIDR; CYP1B1; ABCC2; INSR; MDM4; CHD1; TUBB2A; CBR3; IRS1; GNL3; NOS1; ABCB1; PERP; EPHA6; TOP2A; SERPINE1; SLCO1B1; CCNK; ERBB2; HMMR; TP53; MISP; FOXP3 2024-02-07 Erdafitinib N Y N N 2019 N DB12147 L01EN01 CHEMBL3545376 Locally Advanced, Susceptible FGFR3 or FGFR2 genetic alterations, Condition has progressed during or following at least one line of prior platinum- containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy urothelial carcinoma; Metastatic Susceptible FGFR3 or FGFR2 genetic alterations, Condition has progressed during or following at least one line of prior platinum- containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy Metastatic Urothelial Carcinoma FGFR2; FGFR3; CYP2C9; FGFR4; FGFR1 2024-02-07 Eribulin Y Y N N 2010 Y DB08871 L01XX41 CHEMBL1683590 Metastatic Liposarcoma; Refractory, metastatic Breast cancer; Unresectable Liposarcoma TUBB4A; TUBA3C; ERBB2; TUBB3; ESR1; TUBB2A; CYP3A4; TUBB1; ESR2; CDK2; TUB; TUBB8; TUBA1A; TUBB6; TUBA3E; TUBB2B; TUBA4A; TERT; TUBA1B; TUBA1C; TUBB; PGR; TUBB4B 2024-02-07 Erlotinib Y Y N Y 2004 Y DB00530 L01EB02 CHEMBL553 Locally Advanced Non-Small Cell Lung Cancer; Locally Advanced Pancreatic Cancer; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Pancreatic Cancer Metastatic ERRFI1; FGFR3; NRG1; PKN2; FLT1; MAP3K1; FLT4; JAK2; SLK; HIPK4; MET; BIRC5; ROS1; LYN; MKNK2; ERBB2; ABL1; ABCB1; KDR; CYP1A2; LTK; PTEN; ERBB3; ERBB4; CYP2D6; APC; SYK; ALK; NF1; KRAS; FRK; IGF1R; CBL; PRKD2; FGFR4; AURKB; RET; AR; CLK4; PIK3CA; TP53; BRAF; EGFR; NF2; MAPK1; UGT1A1; MINK1; DDR2; BLK; YES1 2024-02-07 Estramustine N Y Y N 1981 N DB01196 L01XX11 CHEMBL1575 Metastatic Hormone Refractory Prostate Cancer BAX; KLK3; BLM; KAT2A; BCL2; VDR; TDP1; AR; POLK; USP1; HEXB 2024-02-07 Etoposide N Y Y Y 1983 Y DB00773 L01CB01 CHEMBL44657 Acute Lymphoblastic Leukaemias (ALL); Acute Myeloid Leukemia (AML); Advanced Hodgkin's Lymphoma; Ewing's Sarcoma; Merkel cell cancer; Multiple Myeloma (MM); Neuroblastomas; Neuroendocrine Tumours; Non-Hodgkin's Lymphoma (NHL); Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Prostate Cancer; Retinoblastoma; Sarcoma, Osteogenic; Small Cell Lung Cancer (SCLC); Wilms' tumor; Locally advanced Thymoma; Metastatic Thymic Cancer; Refractory Sarcoma; Refractory Testicular cancer SF3B1; SLIT1; PLA2G1B; TOP2A; XIAP; E2F1; ABCC3; CYP2D6; TNFSF13B; KLK3; GSTM1; FGFR1; SLCO1B1; PGP; NCOA3; GSTP1; GMNN; BTF3P11; ABCC1; TP53; TGFB1; EIF4E; MAPK3; HSPB2; BCL2; NTRK3; CHEK1; SLC2A4; CYP1A2; UGT1A10; TOP2B; ACTR2; YAP1; CYP3A4; IGF2; DYNC2H1; MYCN; PAPOLA; AFP; NCOA1; TBP; ALK; CYP2C19; BAX; NQO1; GSTT1; MUC16; DDIT3; ITGAL; GLP1R; CYP2C9; ATM; PLA2G6; MAPK1; NR4A1; GDF15; BLMH 2024-02-07 Everolimus Y Y N N 2009 Y DB01590 L04AA18; L01EG02 CHEMBL1908360 Subependymal giant cell astrocytoma, tuberous sclerosis complex; Advanced Carcinoid tumor; Locally advanced gastrointestinal origin Progressive Neuroendocrine Tumors; Locally advanced lung origin Progressive Neuroendocrine Tumors; Metastatic gastrointestinal origin Progressive Neuroendocrine Tumors; Metastatic lung origin Progressive Neuroendocrine Tumors; Pancreatic origin Progressive Neuroendocrine Tumors; Refractory Advanced Renal Cell Carcinoma; Refractory Waldenstrom's Macroglobulinaemia; Refractory, advanced Breast cancer; Unresectable gastrointestinal origin Progressive Neuroendocrine Tumors; Unresectable lung origin Progressive Neuroendocrine Tumors MTOR; ESR1; TSC1; PIK3CA; RPTOR; AR; ERBB2; CTNNB1; ARID1A; FGFR4; HRAS; FLT3; ATM; PBRM1; AKT1; AKT2; KDM5C; STK11; BRAF; NRAS; NF1; ESR2; NF2; KRAS; RET; PIK3R1; FLCN; CDKN2A; PTEN; VHL; AKT3; FKBP1A; BAP1; TSC2 2024-02-07 Exemestane N Y Y N 1999 Y DB00990 L02BG06 CHEMBL1200374 Early Breast Cancer; Refractory, advanced Breast cancer CYP1B1; KMT2C; IGF1R; ERBB2; ESR1; AKR1C3; BGLAP; PGR; CYP19A1; TUBB1; UGT2B17; NFE2L2; MAP4K4; AR; ESR2; TCL1A 2024-02-07 Fedratinib Y Y N N 2019 N DB12500 L01EJ02 CHEMBL1287853 JAK2; FLT3 2024-02-07 Fludarabine N Y Y Y 1991 Y DB01073 L01BB05 CHEMBL1568 B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory; Refractory Non-Hodgkin's lymphoma POLD1; ADA; CYP2B6; XIAP; DCK; PRIM2; POLA2; POLD3; RRM1; POLE; POLD4; PRIM1; SLCO1B1; POLE2; POLD2; ADH1A; BAX; MPO; CXCL12; SLC29A1; RRM2; NFE2L2; RRM2B; IKZF1; SULT2B1; POLE3; SMAD3; SLC22A12; POLA1; PIK3CG; ATM; CD40; CYP2E1 2024-02-07 Fluorouracil N Y Y Y 1962 Y DB00544 L01BC02 CHEMBL185 Breast Cancer; Malignant Neoplasm of Colon; Malignant Neoplasm of Pancreas; Malignant Neoplasm of Stomach; Rectal Carcinoma; Superficial Basal Cell Carcinoma HSPA5; EXO1; REV3L; ABCB1; MYB; ERCC1; MUTYH; KRAS; RALBP1; TYMS; CYP3A4; IL2RA; UPB1; KLC1; WNT5B; TP53; TOP2A; CBR3; XRCC3; ABCC5; DPYD; IL11; PARD3B; TSHB; IRS1; OSGEP; FGFR2; TPT1; PERP; GNAS; EGFR; DLG5; RBX1; CCNK; BRAF; INSR; FGFR4; HBB; TMEM167A; SMAD4; FPGS; ABCG1; PSMB3P1; AURKA; CCND1; CDKN1A; CYP2C8; NOS1; ALDH3A1; PIK3R2; ABCC4; CXCL8; TYMP; CYP19A1; PTPRC; COLEC10; NLGN1; ITGAL; NT5C1A; SLC22A16; SLC19A1; PIK3CA; ATM; SCN1A; ATRX; CYP2A6; GALNT14; CYP1B1; APEX1; RAD51C; ABCC2; CBR1; MEGF11; HMMR; NRAS; CYP2C19; PPP2R5D; IGFBP3; CYP2E1; PTEN; BDNF; KLC3; PALB2; CDC25C; GNL3; ABCC11; FAS; MTHFR; MUC2; OR10AE3P; SHMT1; IL6R; DTYMK; TWIST1; FOXO1; RGS5; ALCAM; SELE; MECP2; CHN2; LGR5; DKK1; BAX; BIRC5; TP53AIP1; E2F1 2024-02-07 Fluoxymesterone N Y N N 1956 Y DB01185 G03BA01 CHEMBL1445 Inoperable, metastatic Breast cancer PRL; AR; NR3C1 2024-02-07 Flutamide N Y Y N 1989 Y DB00499 L02BB01 CHEMBL806 C Prostatic Carcinoma; Stage B2 Prostatic Carcinoma; Stage D2 Prostatic carcinoma PEBP1; AR; NFE2L2; EHMT2; CDKN1A; AQP9; RORC; CYP2C19; CYP1A2; CYP3A4; VIP; IL2RA; G6PD; KLK3; MPO; BIRC5; NR1I2; CYP2C9; TH 2024-02-07 Fotemustine Y N N N DB04106 L01AD05 CHEMBL549386 Metastatic Melanoma MGMT; TXNRD1 2024-02-07 Fruquintinib N Y N N 2023 N DB11679 L01EK04 CHEMBL4303214 Metastatic Colorectal Cancer FLT1; KDR; FLT4 2024-02-07 Fulvestrant Y Y N N 2002 Y DB00947 L02BA03 CHEMBL1358 Advanced or Metastatic Breast Cancer; Refractory, advanced Breast cancer; Refractory, metastatic Breast cancer ESR1; FGFR2; PGR; NOS1; BDNF; ESR2; PTEN; CDK6; PIK3CA; ESRRA; ERBB2; CCNE1; ALK; XIAP; RB1; CYP1A2; EML4; EPHX2; FGF2; TP53; PIK3CG; TFPI 2024-02-07 Futibatinib Y Y N N 2022 N DB15149 L01EN04 CHEMBL3701238 Locally Advanced Intrahepatic Cholangiocarcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Unresectable Intrahepatic Cholangiocarcinoma FGFR2; FGFR1; BRAF; NRAS; FGFR3; FGFR4 2024-02-07 Gefitinib Y Y N Y 2003 Y DB00317 L01EB01 CHEMBL939 Metastatic Non-Small Cell Lung Cancer EGFR; MAPK14; KRAS; PIM3; CYP2D6; RELA; ERBB3; IRAK4; ALK; ABCB1; ERBB2; LYN; TNK2; PTEN; CHEK2; BRSK1; MAPK10; CRKL; CYP3A5; CAMK2D; HIPK4; MET; MAPK8; CEACAM5; ERBB4; MAPT; YES1; IRAK1; PIK3CA; IGF1R; PRKD2; SIRT2; PBK; PLAU; PHKG2; FLT4; PIM1; BLK; BRAF; ROS1; MAPK9; AXL; EMP1; HCK; MINK1; SMO; FRK; GMNN; CAMK2G; IGF2; SIK2; LIMK1; LCK; MKNK2; MAP4K5; MAP3K1; SLK; CYP2C9; MAP4K4; CSNK1D; PRKD3 2024-02-07 Gemcitabine N Y Y Y 1996 Y DB00441 L01BC05 CHEMBL888 Advanced Ovarian Cancer; Bladder Transitional Cell Carcinoma Stage IV; Cervical Cancers; Cutaneous T-Cell Lymphoma (CTCL); Head and Neck Carcinoma; Hodgkins Disease (HD); Locally Advanced Pancreatic Adenocarcinoma; Mesothelioma; Metastatic Breast Cancer; Non-Small Cell Lung Cancer Stage IIIB; Non-small Cell Lung Cancer (NSCLC), Stage IV; Non-small Cell Lung Cancer Stage IIIA; Small Cell Lung Cancer (SCLC); Stage 4 Pancreatic adenocarcinoma SLC29A1; IGF2; PPCDC; POLD4; TNC; ACSS2; DDX53; OR4D6; RRM2B; TGM2; POLD1; ETS2; BTRC; SLCO1B1; HLA-C; IDH1; CBL; NT5C1A; POLR1G; CDA; HRAS; PIK3CA; CYP2C8; TNF; WEE1; RRM1; POLE2; NRG1; DOCK8; C6orf15; HCP5; PRRC2A; PPP1R18; MTHFD1; NRAS; SMAD4; SH2D5; TP53; BRCA1; MSH5; ESR2; UBASH3B; ALG10; PALB2; RRM2; ERCC1; ALOX5AP; CHEK1; FHL2; SERPINA5; BAZ2B; MS4A2; ERBB2; GPX5; POLE; RAF1; BRCA2; FANCC; XRCC1; MUCL3; PSORS1C1; PRB2; PPP1R13L; POLE3; FGFR3; DCP1B; POLD3; TENT4A; PRIM1; ATAT1; CDC5L; PRIM2; KLC3; SLC29A2; CAMK4; NT5C; POLD2; SERPINC1; CDSN; BRAF; XYLT2; WWOX; FKBP5; KRAS; CDKN2A; ATRX; PTEN; POLA2; CIP2A; POLA1; AR 2024-02-07 Gemtuzumab Ozogamicin Y Y N N 2000 N DB00056 L01FX02 CHEMBL1201506 Acute Myeloid Leukemia (AML); Refractory Acute Myelogenous Leukemia (AML); Relapsed Acute Myelogenous Leukemia (AML) SLCO1B1; SULT2B1; ADH1A; ABCB1; SLC22A12; CYP2E1; CHEK1; CD33; PML 2024-02-07 Gilteritinib Y Y N N 2018 N DB12141 L01EX13 CHEMBL3301622 Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations AXL; FLT3; BRAF; CBL; NRAS; ALK; EML4; KIT; JAK3; IDH2; JAK2 2024-02-07 Glasdegib Y Y N N 2018 N DB11978 L01XJ03 CHEMBL2043437 Acute Myeloid Leukemia (AML) SMO; MTOR; FLT3 2024-02-07 Glofitamab Y Y N N 2023 N DB16371 L01FX28 CHEMBL4298092 Diffuse Large B-Cell Lymphoma (DLBCL), Large B Cell Lymphoma, Primary Mediastinal (Thymic) Large B Cell Lymphoma (PMBCL), Refractory Diffuse Large B Cell Lymphoma (DLBCL), Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Relapsed Diffuse Large B-cell Lymphoma (DLBCL), Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Not Otherwise Specified CD3D; CD3E; MS4A1; CD3G 2024-02-07 Goserelin N Y Y N 1989 N DB00014 L02AE03 CHEMBL1201247 Advanced Breast Cancer; Early Breast Cancer; Advanced carcinoma of the prostate; Stage M1 hormone dependent carcinoma of the prostate; Stage T2b carcinoma of the prostate; Stage T2c carcinoma of the prostate; Stage T3 carcinoma of the prostate; Stage T4 carcinoma of the prostate ESR2; LHCGR; GSR; ESR1; GNRHR; MYOD1; PGR; GNRH1 2024-02-07 Histamine dihydrochloride Y Y N N 1939 N DB05381 L03AX14 CHEMBL90 Acute Myeloid Leukaemia SLC29A4; HRH4; HRH2; HRH1; EHMT2; USP1; LMNA 2024-02-07 Histrelin N Y N N 1991 N DB06788 L02AE05 CHEMBL1201255 Advanced Prostate Cancer GNRHR; GNRHR2 2024-02-07 Hydroxyurea N Y N N 1967 Y DB01005 L01XX05 CHEMBL467 Essential Thrombocythemia (ET); Head and Neck Carcinoma; Melanomas; Ovarian Cancer Metastatic; Polycythemia Vera (PV); Chronic, refractory Myeloid Leukemia; Inoperable Ovarian cancer MAP3K5; BLM; RRM2; RRM2B; SIN3A; EIF4E; KLF4; CP; HRAS; ABL1; PTH; ASS1; DNMT1; DNTT; CYP3A4; DUSP1; RRM1 2024-02-07 Ibritumomab Tiuxetan Y Y N N 2002 N DB00078 V10XX02 CHEMBL1201606 Follicular Non-Hodgkin's Lymphoma; Follicular Non-Hodgkin's Lymphoma Refractory MS4A1 2024-02-07 Ibrutinib Y Y N N 2013 N DB09053 L01EL01 CHEMBL1873475 Chronic Lymphocytic Leukaemia (CLL); Mantle Cell Lymphoma (MCL); Waldenstrom's Macroglobulinemia (WM) BTK; YES1; MYD88; CYP2D6; PLCG2; MYC; LYN; FLT3; BMX; TP53; SMAD3; EGFR; ERBB2; ATM; PIM1; BLK; CSF3R 2024-02-07 Idarubicin N Y Y N 1990 Y DB01177 L01DB06 CHEMBL1117 Acute Myeloid Leukemia (AML) POLK; TOP2A; USP1; SLCO1B1; DRD1; NT5C3A; POLH; DNMT3A; ATAD5; FEN1; FLT3; AR; RECQL; RAPGEF4; CBX1; ADH1A; EHMT2; CYBA; SLC22A12; SULT2B1; BLM; ABCB1; KCNH2; ATXN2; POLI; PPARD; RAC2; CSF2; MTOR; IDH1; MPHOSPH8; POLB; WRN; DCK; NCF4; HTT; MAPT; RAPGEF3; APEX1; THRB; PLK1; ETV6; CYP2E1; ERG 2024-02-07 Idecabtagene Vicleucel Y Y N N 2021 N DB16665 L01XL07 CHEMBL4298199 Refractory Multiple Myeloma, Relapsed Multiple Myeloma TNFRSF17 2024-02-07 Idelalisib Y Y N N 2014 N DB09054 L01EM01 CHEMBL2216870 Relapsed Chronic Lymphocytic Leukemia; Relapsed Small Lymphocytic Lymphoma; Relapsed follicular B-cell non-Hodgkin lymphoma PIK3CD; BRAF; PIK3CA; TP53; PTEN 2024-02-07 Ifosfamide N Y Y Y 1988 Y DB01181 L01AA06 CHEMBL1024 Cancer, Bladder; Cervical Cancers; Ewing's Sarcoma; Head and Neck Carcinoma; Lymphoma, Hodgkins; Malignant Neoplasm of Pancreas; Non-Hodgkin's Lymphoma (NHL); Ovarian Cancer; Sarcoma, Osteogenic; Small Cell Lung Cancer (SCLC); Soft Tissue Sarcoma (STS); Testicular Germ Cell Cancer; Advanced thymic carcinoma TERC; GSTP1; DNMT1; HSPA4; TP53; MGMT; CYP2B6; NR1I2; ALK; CYP2A6; IL6 2024-02-07 Imatinib Y Y N Y 2001 Y DB00619 L01EA01 CHEMBL941 Chordomas; Chronic Eosinophilic Leukemia (CEL); Chronic Myeloid Leukemia (CML); Desmoid Tumors; FIP1L1-PDGFRa fusion kinase status unknown Chronic eosinophilic leukemia; Metastatic Gastrointestinal Stromal Tumor; Metastatic Melanoma; Myelodysplastic Syndromes (MDS); Refractory Acute Lymphoblastic Leukemia; Metastatic Dermatofibrosarcoma protuberans; Newly diagnosed Acute Lymphoblastic Leukaemia; Newly diagnosed, chronic phase Chronic myeloid leukemia; Recurrent Dermatofibrosarcoma protuberans; Refractory, accelerated phase Chronic myeloid leukemia; Refractory, blast crisis Chronic myeloid leukemia; Refractory, chronic phase Chronic myeloid leukemia; Systemic mastocytosis with associated hematological neoplasm; Unresectable Gastrointestinal stromal tumor NTRK1; PDGFRA; RET; BRAF; ABL2; KIT; ABL1; ALK; SMAD3; SYK; CD40LG; quinone reductase 2; FIP1L1; PDGFRB; ABCB4; CYP2B6; PRKCH; IKZF1; LYN; TAOK1; PDGFB; IDH1; BCR; ABCB1; CSF1R; MAPK10; EYA2; CLK4; ABCC4; LCK; ABCG2; IRAK1; RAD52; CYP2F1; SLC19A1; ULK3; BCL2L11; NF1; PTEN; BIRC5; HCK; CYP3A5; GSTT1; NF2; RUNX1; SLCO1A2; CSF3R; SFN; HGF; KRAS; RUNDC3B; FGF2; CHST1; PIK3CG; UGT2A1; MYC; PVT1; CYP3A4; JAK2; EGFR; CTNNB1; ABCA3; XIAP; FRK; RCSD1; DDR1; SLC2A4; FLT3; ABI1; YES1 2024-02-07 Imiquimod Y Y N N 1997 Y DB00724 D06BB10 CHEMBL1282 Superficial Basal Cell Carcinoma GMNN; IFNA1; TLR7 2024-02-07 Infigratinib N Y N N 2021 N DB11886 L01EN03 CHEMBL1852688 Unresectable, locally advanced Cholangiocarcinomas, Unresectable, metastatic Cholangiocarcinomas FGFR3; KIT; FGFR4; NRAS; FGFR1; FGFR2; PIK3R3; PIK3R2; PIK3R5; PIK3R4; PIK3C3; MTOR; PIK3CA; PTEN; PIK3C2B; PIK3CB; PIK3CG; PIK3CD; PIK3C2G; PIK3C2A; PIK3R1; PIK3R6 2024-02-07 Inotuzumab Ozogamicin Y Y N N 2017 N DB05889 L01FB01 CHEMBL2108611 Refractory B-cell precursor acute lymphoblastic leukemia; Relapsed B cell precursor Acute lymphoblastic leukemia CD22; BCR; ABL1 2024-02-07 Interferon Alfa-2b Y Y N N 1986 N DB00105 L03AB05 CHEMBL1201558 Hairy Cell Leukemia (HCL); Kaposi's sarcoma; Melanoma, Malignant IFNAR2; TP53; IFNA2; TGFB1; IFNAR1; FTO; ITPA; EIF2AK2; IFNG; IFNL4; CSF2; IL6; BAX; IL18 2024-02-07 Iobenguane I-131 N Y N N 1994 N DB06704 V09IX01; V09IX02; V10XA02 CHEMBL1615779 Metastatic Pheochromocytoma; Metastatic Neuroblastoma; Primary Neuroblastomas; Primary Pheochromocytomas; Unresectable, locally advanced iobenguane-scan positive Paraganglioma; Unresectable, locally advanced iobenguane-scan positive Pheochromocytomas; Unresectable, metastatic iobenguane-scan positive Paraganglioma; Unresectable, metastatic iobenguane-scan positive Pheochromocytomas TH; SLC6A2 2024-02-07 Ipilimumab Y Y N N 2011 N DB06186 L01FX04 CHEMBL1789844 Advanced Renal Cell Carcinoma; Cutaneous Melanoma; Hepatocellular Carcinoma; Metastatic Melanoma; Unresectable Melanoma; Metastatic MSI-H/dMMR colorectal cancer CTLA4; CD274; BRAF; MDM2; EGFR; HLA-A; ALK; NRAS; PBRM1; TP53; MSH6; MLH1 2024-02-07 Irinotecan N Y Y Y 1996 Y DB00762 L01CE02 CHEMBL481 Esophageal Cancers; Ewing's Sarcoma; Glioblastomas; Malignant Neoplasm of Pancreas; Malignant Neoplasm of Stomach; Metastatic Colorectal Carcinoma; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Rhabdomyosarcomas; Small Cell Lung Cancer (SCLC); Recurrent, IV-B Cervical cancer; Recurrent, metastatic Colorectal carcinoma; Refractory, metastatic Pancreatic adenocarcinoma SEMA3C; TGFB1; PALB2; HSD17B10; TYMS; BCHE; TOP1; RGS5; ABCC5; ATM; E2F1; CES1; ISG15; UGT1A1; AREG; GSTM1; ABCC1; DCBLD1; KRAS; PIN1; MTHFR; RUNX3; AR; RAD50; MAPK10; PIK3CA; KCNQ5; CES2; UGT1A8; TOP1MT; KLC1; PLCB1; UBE2I; BRAF; DKK1; XRCC3; ABCG1; SHMT1; ABCC4; SLC19A1; GSTP1; PDZRN3; ATRX; BIRC5; RALBP1; C8orf34; ALK; TP53; MAP2K1; UGT1A10; MGMT; TGFBR2; TYMSOS; UGT1A; TDP1; FGFR3; CDKN1A; SLCO1B3; NRAS 2024-02-07 Irinotecan Liposome Y Y N N 1996 Y DB00762 L01XX19 CHEMBL481 Esophageal Cancers; Ewing's Sarcoma; Glioblastomas; Malignant Neoplasm of Pancreas; Malignant Neoplasm of Stomach; Metastatic Colorectal Carcinoma; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Rhabdomyosarcomas; Small Cell Lung Cancer (SCLC); Recurrent, IV-B Cervical cancer; Recurrent, metastatic Colorectal carcinoma; Refractory, metastatic Pancreatic adenocarcinoma SEMA3C; TGFB1; PALB2; HSD17B10; TYMS; BCHE; TOP1; RGS5; ABCC5; ATM; E2F1; CES1; ISG15; UGT1A1; AREG; GSTM1; ABCC1; DCBLD1; KRAS; PIN1; MTHFR; RUNX3; AR; RAD50; MAPK10; PIK3CA; KCNQ5; CES2; UGT1A8; TOP1MT; KLC1; PLCB1; UBE2I; BRAF; DKK1; XRCC3; ABCG1; SHMT1; ABCC4; SLC19A1; GSTP1; PDZRN3; ATRX; BIRC5; RALBP1; C8orf34; ALK; TP53; MAP2K1; UGT1A10; MGMT; TGFBR2; TYMSOS; UGT1A; TDP1; FGFR3; CDKN1A; SLCO1B3; NRAS 2024-02-07 Isatuximab Y Y N N 2020 N DB14811 L01FC02 CHEMBL3545131 Multiple Myeloma (MM) CD38 2024-02-07 Ivosidenib Y Y N N 2018 N DB14568 L01XX62 CHEMBL3989958 Newly diagnosed, refractory or relapsed Acute Myeloid Leukemia; Relapsed or refractory Myelodysplastic Syndromes with IDH1 mutation; Locally Advanced or Metastatic Cholangiocarcinoma with IDH1 mutation IDH2; IDH1 2024-02-07 Ixabepilone N Y N N 2007 N DB04845 L01DC04 CHEMBL1201752 Locally Advanced Breast Cancer (LABC); Metastatic Breast Cancer TUBB4B; TUBA1A; PGR; TUBB1; ESR1; TUBB3; ESR2; TUBA1B; TUBB; CYP3A4; TUBA3E; TUBB4A; TUBB6; ERBB2; TUBB2A; TUBA4A; TUBB2B; TUBB8; TUBA3C; TUB; TUBA1C 2024-02-07 Ixazomib Y Y N N 2015 N DB09570 L01XG03 CHEMBL2141296 Multiple Myeloma (MM) PSMA7; PSMB10; PSMA2; PSMA4; PSMB11; PSMD2; PSMD1; PSMA1; PSMD14; PSMD12; PSMB8; PSMC1; TP53; PSMD13; SEM1; PSMB3; PSMB9; PSMB5; PSMD11; PSMC5; ADRM1; PSMC6; PSMA8; PSMA5; PSMC2; PSMA3; PSMB1; PSMD7; PSMD4; PSMB6; PSMD3; PSMD6; PSMB7; PSMA6; PSMC4; EML4; ALK; PSMB2; PSMD8; PSMC3; PSMB4 2024-02-07 Lanreotide N Y Y N 2007 N DB06791 H01CB03 CHEMBL1201185 Unresectable, locally advanced enteropancreatic neuroendocrine tumors; Unresectable, locally advanced gastroenteropancreatic neuroendocrine tumors; Unresectable, metastatic enteropancreatic neuroendocrine tumors; Unresectable, metastatic gastroenteropancreatic neuroendocrine tumors EDN1; SSTR1; SSTR2; SSTR5 2024-02-07 Lapatinib Y Y N N 2007 Y DB01259 L01EH01 CHEMBL554 Metastatic Breast Cancer; Refractory, advanced Breast cancer; Refractory, metastatic Breast cancer ERBB2; PGR; EGFR; HLA-DRB1; BRAF; AURKB; ESR1; HLA-DQA1; PTEN; PIK3CA; RET; MET; ERBB4; ERBB3; CYP3A4; ABCB11; BIRC5; ESR2; CDKN1B; YES1; NF2; CCND1; NRG1; CYP3A5; KRAS; EEF2K 2024-02-07 Larotrectinib Y Y N N 2018 N DB14723 L01EX12 CHEMBL3889654 NTRK1 Fusion Positive; NTRK2 Fusion Positive; NTRK3 Fusion Positive NTRK1; NTRK3; NTRK2 2024-02-07 Lenalidomide Y Y N Y 2005 Y DB00480 L04AX04 CHEMBL848 Chronic Lymphocytic Leukemia (CLL) - Refractory; Follicular Lymphoma (FL); Mantle Cell Lymphoma (MCL); Marginal Zone Lymphoma (MZL); Multiple Myeloma (MM); Myelodysplastic Syndrome; Refractory Diffuse Large B Cell Lymphoma TP53; CTNNB1; DDB1; FGF2; KDR; RBX1; CRBN; VEGFA; CUL4A; VEGFC; VEGFB; TNFSF11; TNF 2024-02-07 Lenvatinib Y Y N N 2015 N DB09078 L01EX08 CHEMBL1289601 Advanced Renal Cell Carcinoma; Locally recurrent radioactive iodine-refractory Thyroid cancer; Metastatic radioactive iodine-refractory Thyroid cancer; Progressive radioactive iodine-refractory Thyroid cancer FGFR2; KDR; NRAS; PDGFRA; YES1; FLT1; RET; PDGFRB; BRAF; KIT; FLT4; FGFR1 2024-02-07 Letrozole N Y Y N 1997 Y DB01006 L02BG04 CHEMBL1444 Advanced Breast Cancer; Early Breast Cancer; Ovarian Epithelial Cancer; Advanced HR + HER2 - breast cancer; Metastatic HR + HER2 - breast cancer ESR1; ESR2; CYP19A1; PTEN; RB1; SFTPA1; PGR; CTNNB1; CYP3A4; ERBB2; CYP2A6; KIT; TNFRSF11B; KMT2C; CDKN2A; PIK3CA; TNFSF11; MMP2; CYP1B1 2024-02-07 Leuprolide N Y N N 1985 Y DB00007 L02AE51; L02AE02 CHEMBL1201199 Advanced Prostate Cancer GNRHR 2024-02-07 Lisocabtagene Maraleucel Y Y N N 2021 N DB16582 CHEMBL4297236 Grade 3b Follicular Lymphoma; High-grade B-cell Lymphoma (HGBCL); Primary mediastinal large B-cell lymphomas; Refractory Diffuse Large B Cell Lymphoma; Refractory Large B-cell Lymphoma; Relapsed Large B-cell Lymphoma; Relapsed, Diffuse Large B-cell Lymphoma CD19 2024-02-07 Lomustine N Y Y N 1976 N DB01206 L01AD02 CHEMBL514 Primary Brain Tumors; Refractory Hodgkin Lymphoma; Tumors Metastatic to Brain MGMT; IDH1; ADK; EGFR 2024-02-07 Loncastuximab Tesirine Y Y N N 2021 N DB16222 L01FX22 CHEMBL4297778 Refractory Large B-cell Lymphoma, Relapsed Large B-cell Lymphoma CD19 2024-02-07 Lorlatinib Y Y N N 2018 N DB12130 L01ED05 CHEMBL3286830 Progressive, metastatic Anaplastic lymphoma kinase-positive Metastatic Non-Small Cell Lung Cancer NRAS; ALK; EML4; TP53; ROS1; HRAS; RB1; BRAF; PIK3CA; FGFR1 2024-02-07 Lu 177-Dotatate Y Y N N 2018 N DB13985 V10XX04 CHEMBL3989924 Gastroenteropancreatic Neuroendocrine Tumors SSTR1; SSTR5; SSTR3; SSTR4; SSTR2 2024-02-07 Lurbinectedin N Y N N 2020 N DB12674 L01XX69 CHEMBL4297516 Metastatic Small Cell Lung Cancer 2020-09-17 Lutetium Lu 177 Vipivotide Tetraxetan Y Y N N 2022 N DB16778 V10XX05 CHEMBL4594406 Metastatic Castration Resistant Prostate Cancer (CRPC) FOLH1 2024-02-07 Margetuximab N Y N N 2020 N DB14967 L01FD06 CHEMBL2364649 HER2-positive Metastatic Breast Cancer ERBB2; FCGR2B; FCGR2A; ERBB3; FCGR3A 2024-02-07 Mechlorethamine Y Y N N 1949 N DB00888 L01AA05 CHEMBL427 Carcinoma, Bronchogenic; Chronic Lymphocytic Leukaemia (CLL); Hodgkins Disease (HD); Lymphoma, Diffuse; Mycosis Fungoides (MF); Polycythemia Vera (PV); Stage I Mycosis Fungoides; Malignant effusion MMP2; TSHB; CXCR2; ERBB2; MT-CO1; CSF2; GSTP1; BAX; XRCC1; NOS1; GSR 2024-02-07 Medroxyprogesterone N Y Y N 1959 Y DB00603 G03DA02; G03AC06; L02AB02 CHEMBL717 Metastatic Renal Cell Carcinoma; Metastatic Endometrial carcinoma ESR1; PGR; CYP3A5; CYP1B1; VDR; MMP1; BAX 2024-02-07 Megestrol Acetate N Y Y N 1971 Y DB00351 G03DB02; G03AC05; L02AB01 CHEMBL1201139 Advanced Breast Cancer; Advanced Endometrial Cancer ESR1; IL15; NPSR1; IL2RA; AR; KLK3; PGR; ABCB1; NFE2L2 2024-02-07 Melphalan N Y Y Y 1964 Y DB01042 L01AA03 CHEMBL852 Multiple Myeloma (MM); Ovarian Epithelial Cancer; Severe Hodgkin Lymphoma NFE2L2; SLC7A5; ABCB1; EHMT2; POLR1G; ABL1; FANCC; MGMT; AR; TP53; RORC; OPLAH; CTLA4; GSTP1; PLAT; NR1H4; ABCC1; CYP3A4; CDKN1A; CDK12; IFNG 2024-02-07 Melphalan Flufenamide Y Y N N 2021 N DB16627 L01AA10 CHEMBL4303060 Relapsed Or Refractory Multiple Myeloma NFE2L2; SLC7A5; ABCB1; EHMT2; POLR1G; ABL1; FANCC; MGMT; AR; TP53; RORC; OPLAH; CTLA4; GSTP1; PLAT; NR1H4; ABCC1; CYP3A4; CDKN1A; CDK12; IFNG 2024-02-07 Mercaptopurine Y Y N Y 1953 Y DB01033 L01BB02 CHEMBL1425 Acute Lymphoblastic Leukaemias (ALL); Acute Promyelocytic Leukemia (APL); Lymphoma, Lymphoblastic TP53; ALDH1A1; SLC29A2; TPMT; HPRT1; CYP2C9; FOLH1; TDP1; KDM4E; BAZ2B; NUDT15; VCAM1; HBB; IMPDH1; XDH; KDM4A; HLA-DQA1; IL2RA; CYP2C19; PRPS1; HLA-DRB1; CYP1A2; PPAT; IDH1; GATA3; NT5C2; MTHFR; FTO; CYP3A4; SLC28A3; NFE2L2; SLCO1B1; GSTP1; CYP2D6; GNMT 2024-02-07 Methotrexate Y Y N Y 1953 Y DB00563 L04AX03; L01BA01 CHEMBL34259 Acute Lymphocytic Leukemia (ALL); Acute Promyelocytic Leukemia (APL); Breast Cancer; Cancer, Bladder; Central Nervous System Lymphoma; Choriocarcinoma; Head and Neck Carcinoma; Meningeal leukemia; Sarcoma, Osteogenic; Small Cell Lung Cancer (SCLC); Soft Tissue Sarcoma (STS); Squamous Cell Carcinoma of Lung; Advanced Alibert-Bazin syndrome; Advanced non-Hodgkin lymphoma; Nonleukemic meningeal cancer SLC22A11; CCND1; ABCC4; PYGL; ENG; FOLR1; NFE2L2; BAX; HLA-E; DHFR; CDK9; KLRD1; SPECC1L; BIRC5; HSPB2; POLH; SLC16A7; NTRK3; C1orf167; NR1I2; ALK; GSTT1; NCOA3; FCGR3B; HGF; NOS3; EHMT2; TLR4; E2F1; GLS; GSTM1; CYP1A2; SLC46A1; S100A8; PPARG; TARDBP; NR3C1; ARID5B; CYP2C9; S100A12; SULT2A1; SLCO1A2; ADORA2A; ENOSF1; TPM3; SOD2; LINC00251; MSH3; VDR; TP53; ERCC2; COL18A1; FOXP3; CYP2C19; FPGS; GATA3; NQO1; CDH2; NOP2; CYP2D6; ATP5F1E; ALOX5; FGFR4; APEX1; MPHOSPH8; HLA-C; TNFAIP3; SLC19A1; IKZF1; ADORA2A-AS1; CYP3A4; PTPN22; ATIC; KIR2DS4; IL2; AFP; BMP7; NTRK1; TAT; GSK3B; SLCO1B1; SLC22A8; SLAMF1; POLB; NALCN; FLT3; TYMS; FOLH1; KCNA1; ICAM3; HSD17B10; ADA; POLI; IDH1; CDKN1B; IL1RN; DOK5; SLC22A9 2024-02-07 Midostaurin Y Y N N 2017 N DB06595 L01EX10 CHEMBL608533 Acute Myeloid Leukemia (AML); Malignant mast cell neoplasm; Systemic mastocytosis with associated hematological neoplasm NTRK3; FGFR1; PIK3CB; KIT; PRKD1; FLT3; PRKCD; PRKCQ; IL6; PRKCG; PRKCE; PIK3CA; PRKCA; STK32B; PRKCH; PDGFRA; PRKCB; NPM1; PRKCI; IL2; HSPA4; CBL; PRKCZ; IDH2; JAK3; PRKD3; JAK2; PDGFRB; YES1; KDR; FGFR3; TNF 2024-02-07 Mifamurtide Y N N N 2009 N DB13615 L03AX15 CHEMBL2107354 High-grade, nonmetastatic Osteosarcoma; Resectable, nonmetastatic Osteosarcoma NOD2 2024-02-07 Mirvetuximab Soravtansine N Y N N 2022 N DB12489 L01FX26 CHEMBL3545132 Platinum Resistant Primary Peritoneal Cancer, Platinum-resistant Epithelial Ovarian Cancer, Platinum drug resistant Fallopian tube cancer TUBB2A; TUBB1; TUBB6; TUBA1B; TUBB8; TUBA1C; TUBA3C; TUBB3; TUBB; TUBA1A; TUBA4A; TUBB4B; FOLR1; TUBA3E; TUBB4A; TUBB2B 2024-02-07 Mitomycin N Y Y N 1981 Y DB00305 L01DC03 CHEMBL105 Adenocarcinoma of the Pancreas; Adenocarcinoma of the Stomach; Breast Cancer; Cancer, Anal; Cancer, Bladder; Cervical Cancers; Head and Neck Carcinoma; Mesothelioma; Non-Small Cell Lung Carcinoma (NSCLC); Low-grade Upper Tract Urothelial Cancer (LG-UTUC) BGLAP; DHFR; TP53; TYMS; CYP2C9; CYP2C19; BRCA1; VWF; IL1A; CGB5; CYP7B1; CYP2D6; FANCC; ABCB1; AR; LGALS2; TAT; XDH; CYP1A2; ABCB4; CYP3A4; MAPK10; KRT18; PALB2 2024-02-07 Mitoxantrone N Y Y N 1987 Y DB01204 L01DB07 CHEMBL58 Acute Lymphocytic Leukemia (ALL); Acute Myeloid Leukemia (AML); Acute Promyelocytic Leukemia (APL); Lymphoma, Hodgkins; Metastatic Breast Cancer; Non-Hodgkin's Lymphoma (NHL); Relapsed Leukemia; Relapsed Lymphomas; Hormone refractory, advanced Prostate cancer; Relapsed Hepatocellular carcinoma CYP3A4; ABCG2; MECP2; MBNL1; GALNT14; POLH; RPSA; POLK; RACGAP1; UGT1A5; MAPK1; SLCO1B1; RECQL; BRCA1; WRN; ARSA; SMAD3; TOP2A; RGS4; BCL2; NSD2; YES1; NFKB1; RAD52; KDM4A; CBX1; EHMT2; HTT; POLI; ABCB1; PIM1; BAX; MPHOSPH8; C10orf67; TP53; DNMT1; FLT3; THPO; BLM; ATAD5; ATXN2; FEN1 2024-02-07 Mobocertinib N Y N N 2021 N DB16390 L01EB10 CHEMBL4650319 Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer EGFR 2024-02-07 Mogamulizumab Y Y N N 2018 N DB12498 L01FX09 CHEMBL1743041 Refractory Mycosis Fungoides/Sezary Syndrome; Relapsed Mycosis Fungoides/Sezary Syndrome CCR4 2024-02-07 Mosunetuzumab Y N N N 2022 N DB15434 L01FX25 CHEMBL4297788 Relapsed follicular lymphoma, Refractory follicular lymphoma CD3D; MS4A1; CD3E; CD3G 2024-02-07 Moxetumomab Pasudotox Y Y N N 2018 N DB12688 L01FB02 CHEMBL1743043 Relapsed/Refractory Hairy Cell Leukemia EEF2; CD22 2024-02-07 Nab-Paclitaxel Y Y N N 2005 Y Not found in DrugBank L01CD01 CHEMBL428647 Advanced Cervical Cancer; Advanced Head and Neck Cancer; Advanced Ovarian Cancer; Advanced Soft Tissue Sarcoma; Esophageal Cancers; Fallopian Tube Cancer; Kaposi's sarcoma; Locally Advanced Non-Small Cell Lung Cancer; Malignant Neoplasm of Stomach; Malignant Peritoneal Neoplasm; Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Melanoma; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Pancreatic Adenocarcinoma Metastatic; Advanced Bladder cancer; Advanced Thymoma; Metastatic Penile cancer; Refractory Small cell lung cancer; Refractory Testicular germ cell cancer SOD2; TUBA3C; TRIM5; FASN; NAT2; FZD3; FGD4; ERCC2; CDKN1A; FCGR2A; LIF; MAP3K1; TUBB4B; RRM1; SYK; EIF4E2; BIRC5; AURKA; TP53; OPRM1; BCL2; ABCB1; TUBA3D; NFE2; EPHA6; TUBA1A; TUBB3; TUBB4A; TUBB; ROS1; ERBB2; TUBA3E; FNTB; GSTP1; EDNRB; PIK3CA; E2F1; ETS2; TLE3; IL2RA; JAK2; CXCL8; ABCC1; GSTT1; TUBA4A; SLCO1B1; AR; FOS; ABCC10; RAD51C; EPHA5; TIGD1; SPIDR; CDK2; NR1I2; GMNN; GSTM1; BDNF; CYP3A; EIF4EBP1; ATM; ABCC3; SLC29A1; ABCC2; DSCAM; TUBB6; TOP2A; TUBB1; RAF1; TUBB2B; TUBA1C; NOP2; FGFR1; ABCG2; MYB; PIK3CG; TYMS; BRCA1; CASP7; NRG1; SLCO1B3; CHEK1; PGP; AFG2A; MMP2; DDIT3; STMN1; PTEN; EGFR; SOX10; MAD1L1; TUBB2A; ACSS2; PDCD4; CASP3; TUBA1B; TUBB8; RB1; MISP; ERCC1; CYP3A5; ARHGEF10; KRAS 2024-02-07 Nab-Sirolimus N Y N N 2021 N DB00877 L04AH01 CHEMBL413 Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa) ADAMTSL4-AS1; MTOR; RBL2; AR; FLCN; APC; POR; NFE2L2; NRAS; TSC1; RPS6KB1; IL10; PRKAA1; EGFR; BAX; DDIT3; IL17A; TP53; ALK; EIF4E; ABCG2; PTEN; HRAS; RB1; TCF7L2; WT1; TGM2; CDKN2A; IL7; JAK2; CRLF2; ITGAL; DCN; PIM1; FBXW7; MMP1; CTLA4; NR1I2; MAPK10; FGFR1; IGFBP1; PGR; RPTOR; PLAU; FKBP4; FGF2; ERBB2; RHEB; IL15; ABCB1; NOS1; FKBP1A; PIK3CA; OPRK1; DDC; NF1; EML4 2024-02-07 Nadofaragene Firadenovec N Y N N 2022 N DB17381 L01XL10 CHEMBL3990041 High risk BCG-unresponsive non-muscle invasive bladder cancer IFNA2 2024-02-07 Naxitamab N Y N N 2020 N DB15965 L01FX21 CHEMBL4297984 High risk, refractory Neuroblastomas of the bone or bone marrow; High risk, relapsed Neuroblastomas of the bone or bone marrow 2022-10-23 Necitumumab Y Y N N 2015 N DB09559 L01FE03 CHEMBL1743047 Metastatic Non-Small Cell Lung Cancer EGFR 2024-02-07 Nelarabine Y Y N N 2005 Y DB01280 L01BB07 CHEMBL1201112 Lymphoblastic lymphoma (Precursor T-lymphoblastic lymphoma/leukemia) refractory; Refractory Acute Lymphoblastic Leukemia POLA1; NT5C2 2024-02-07 Neratinib Y Y N N 2017 N DB11828 L01EH02 CHEMBL180022 Breast Cancer ERBB2; ERBB4; CBL; BRAF; PGR; ESR1; YES1; EGFR; PIK3CA; KDR; ESR2; HERC2 2024-02-07 Nilotinib Y Y N Y 2007 N DB04868 L01EA03 CHEMBL255863 Chronic Phase Chronic Myeloid Leukemia; Refractory Gastrointestinal stromal tumor; Refractory, accelerated phase Chronic myeloid leukemia ABI1; FLT3; BCR; KIT; PDGFRA; ABCG2; UGT1A1; CYP3A4; PDGFRB; NF1; DDR2; ABL1 2024-02-07 Nilutamide N Y N N 1996 Y DB00665 L02BB02 CHEMBL1274 Metastatic Hormone Refractory Prostate Cancer CYP2C19; CYP2D6; AR; CYP3A4; NFE2L2; CYP2C9; PRL; KLK3; CYP1A2 2024-02-07 Nintedanib Y Y N N 2014 Y DB09079 L01EX09 CHEMBL502835 Locally advanced Non-Small Cell Lung Cancer (NSCLC) caused by Adenocarcinoma; Locally recurrent Non-Small Cell Lung Cancer (NSCLC) caused by Adenocarcinoma; Metastatic Non-Small Cell Lung Cancer (NSCLC) caused by Adenocarcinoma FGFR3; KDR; CFLAR; PDGFRB; PDGFRA; FGFR2; FGFR1; FGFR4; FLT1; RET; KIT; FLT4; AKT1; PIK3CA 2024-02-07 Niraparib Y Y N N 2017 N DB11793 L01XK02 CHEMBL1094636 Fallopian Tube Cancer; Ovarian Epithelial Cancer; Primary Peritoneal Cancer PARP1; ATM; MYCN; RAD51C; BRCA1; ATR; ARID1A; FANCA; CHEK2; IDH1; SLFN11; PALB2; PTEN; BRCA2; CDK12; PARP2; BRIP1 2024-02-07 Nirogacestat Hydrobromide N Y N N 2023 N DB12005 L01XX81 CHEMBL4298153 Progressive Desmoid Tumors 2024-02-01 Nivolumab Y Y N Y 2015 N DB09035 L01FF01 CHEMBL2108738 Advanced Renal Cell Cancer; Classical Hodgkin's Lymphoma; Hepatocellular Carcinoma; Low Risk Advanced Renal Cell Cancer; Melanomas; Metastatic Colorectal Cancer (MCRC); Metastatic Melanoma; Metastatic Non-Small Cell Lung Cancer; Metastatic Small Cell Lung Cancer; Metastatic Squamous Cell Carcinoma of the Head and Neck; Metastatic Urothelial Carcinoma (UC); Recurrent Head and Neck Squamous Cell Carcinoma; Unresectable Melanoma; Intermediate risk Advanced Renal Cell Cancer; Locally advanced Urothelial Carcinoma PTEN; CD274; PDCD1; CDK12; BRAF; MDM2; ALK; MLH1; IDH1; PMS2; FGFR3; KRAS; TP53; EGFR; HLA-DRA; NRAS; PBRM1; ARID1A; MDM4; STK11; MSH6; ERBB2 2024-02-07 Obinutuzumab Y Y N N 2013 N DB08935 L01FA03 CHEMBL1743048 Refractory Follicular Lymphoma; Previously untreated Chronic lymphocytic leukemia MS4A1; TP53 2024-02-07 Ofatumumab Y Y N N 2009 N DB06650 L04AA52; L01FA02 CHEMBL1201836 Chronic Lymphocytic Leukaemia (CLL); Chronic Lymphocytic Leukemia (CLL) - Refractory; Progressive Chronic Lymphocytic Leukaemia (CLL); Recurrent Chronic Lymphocytic Leukaemia (CLL) MS4A1 2024-02-07 Olaparib Y Y N N 2014 N DB09074 L01XK01 CHEMBL521686 Fallopian Tube Cancer; Malignant Peritoneal Neoplasm; Metastatic Breast Cancer; Ovarian Epithelial Cancer; Primary Peritoneal Cancer; Advanced deleterious germline or somatic BRCA-mutated advanced epithelial ovarian cancer; Advanced deleterious germline or somatic BRCA-mutated fallopian tube cancer; Advanced deleterious germline or somatic BRCA-mutated peritoneal cancer; Refractory Advanced Ovarian Cancer PPP2R2A; ATM; RAD54L; PARP1; PGR; PARP3; PARP2; BRCA1; ATRX; CHEK1; IDH2; ERBB2; ESR1; ARID1A; PALB2; MYC; KDM6A; BRCA2; ESR2; IDH1; FANCA; MYCN; SF3B1; BARD1; CHEK2; ATR; NRAS; HDAC2; RAD51B; PTEN; PIK3CA; RAD51D; VHL; FANCL; CDK12; BRIP1; BAP1; RAD51C; TP53 2024-02-07 Olaratumab Y Y N N 2016 N DB06043 L01FX10 CHEMBL1743049 Soft Tissue Sarcoma (STS) PDGFRA 2024-02-07 Olutasidenib N Y N N 2022 N DB16267 CHEMBL4297610 Refractory Acute Myeloid Leukemia (AML), Relapsed Acute Myelogenous Leukemia (AML) IDH1 2024-02-07 Omacetaxine Mepesuccinate N Y N N 2009 N DB04865 L01XX40 CHEMBL46286 Refractory, accelerated phase Chronic myeloid leukemia; Refractory, chronic phase Chronic myeloid leukemia BIRC5; ABL1; TERT; FLT3; BCR 2024-02-07 Osimertinib Y Y N N 2015 N DB09330 L01EB04 CHEMBL3353410 Metastatic Non-Small Cell Lung Cancer MET; EGFR; PIK3CA; ERBB2; ROS1; ALK; TP53; CTNNB1; BRAF; PTEN; NRAS 2024-02-07 Oxaliplatin N Y Y Y 2002 Y DB00526 L01XA03 CHEMBL414804 Advanced Colorectal Cancer; Advanced Ovarian Cancer; Advanced Pancreatic Cancer; Chronic Lymphocytic Leukemia (CLL) - Refractory; Colon Cancer Stage III; Esophageal Cancers; Malignant Neoplasm of Stomach; Advanced biliary adenocarcinoma; Refractory Neuroendocrine Tumour; Refractory Non-Hodgkin's lymphoma; Refractory Testicular cancer PIN1; FGFR2; ABL1; KRAS; BRCA1; KLC3; PTGS2; ATP7A; ABCC2; PTEN; DPYD; SELE; PALB2; GNA13; MT1A; PARD3B; MGAT4A; ATP7B; GSTP1; PIK3CA; TP53; ABCC5; ZEB1; DKK1; BAX; ATM; MTHFR; FOXC2; CXCL10; BRAF; BCL2; CSMD1 2024-02-07 Paclitaxel Y Y N Y 1992 Y DB01229 L01CD01 CHEMBL428647 Advanced Cervical Cancer; Advanced Head and Neck Cancer; Advanced Ovarian Cancer; Advanced Soft Tissue Sarcoma; Esophageal Cancers; Fallopian Tube Cancer; Kaposi's sarcoma; Locally Advanced Non-Small Cell Lung Cancer; Malignant Neoplasm of Stomach; Malignant Peritoneal Neoplasm; Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Melanoma; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Pancreatic Adenocarcinoma Metastatic; Advanced Bladder cancer; Advanced Thymoma; Metastatic Penile cancer; Refractory Small cell lung cancer; Refractory Testicular germ cell cancer SOD2; TUBA3C; TRIM5; FASN; NAT2; FZD3; FGD4; ERCC2; CDKN1A; FCGR2A; LIF; MAP3K1; TUBB4B; RRM1; SYK; EIF4E2; BIRC5; AURKA; TP53; OPRM1; BCL2; ABCB1; TUBA3D; NFE2; EPHA6; TUBA1A; TUBB3; TUBB4A; TUBB; ROS1; ERBB2; TUBA3E; FNTB; GSTP1; EDNRB; PIK3CA; E2F1; ETS2; TLE3; IL2RA; JAK2; CXCL8; ABCC1; GSTT1; TUBA4A; SLCO1B1; AR; FOS; ABCC10; RAD51C; EPHA5; TIGD1; SPIDR; CDK2; NR1I2; GMNN; GSTM1; BDNF; CYP3A; EIF4EBP1; ATM; ABCC3; SLC29A1; ABCC2; DSCAM; TUBB6; TOP2A; TUBB1; RAF1; TUBB2B; TUBA1C; NOP2; FGFR1; ABCG2; MYB; PIK3CG; TYMS; BRCA1; CASP7; NRG1; SLCO1B3; CHEK1; PGP; AFG2A; MMP2; DDIT3; STMN1; PTEN; EGFR; SOX10; MAD1L1; TUBB2A; ACSS2; PDCD4; CASP3; TUBA1B; TUBB8; RB1; MISP; ERCC1; CYP3A5; ARHGEF10; KRAS 2024-02-07 Padeliporfin Y N N N 2017 N DB15575 L01XD07 CHEMBL4298112 Low-Risk Prostate Cancer of the one lobe only 2020-09-17 Palbociclib Y Y N N 2015 N DB09073 L01EF01 CHEMBL189963 Advanced Breast Cancer; Metastatic Breast Cancer; Refractory, advanced Breast cancer; Refractory, metastatic Breast cancer ERBB2; CCND2; MST1R; DAPK3; CCND3; SMARCA4; CCNE2; CDK4; FLT3; ESR1; ALK; NRAS; PRKAA1; NEK2; DYRK1A; PGR; CCND1; MAP4K5; CDK9; PIK3CA; MAPK9; CHEK2; ESR2; KRAS; LRRK2; TAOK1; CCNE1; CDKN2A; CDK5; DYRK1B; TP53; PAK4; MAP4K2; PTEN; PRKD3; CHEK1; RET; MET; ROCK2; CDKN2B; CLK4; PRKX; BRAF; MAPK8; CLK2; CDK6; MAP4K4; RB1; RPS6KA3 2024-02-07 Panitumumab Y Y N N 2006 N DB01269 L01FE02 CHEMBL1201827 Metastatic Colorectal Cancer (MCRC) PTEN; TGFA; BRAF; BTC; HBEGF; TP53; MAP2K1; NRAS; EGFR; NRG1; CDKN2A; HRAS; KRAS; EREG; NRG3; AREG; PIK3CA; MET; NRG2 2024-02-07 Panobinostat Y Y N N 2015 N DB06603 L01XH03 CHEMBL483254 Refractory Multiple Myeloma HDAC2; SIRT3; HDAC1; HDAC4; MYCN; HDAC5; CSF1R; SIRT6; HDAC3; SIRT5; HDAC7; BAP1; HDAC9; ACTL6A; HDAC11; HDAC8; HDAC10; SIRT7; BRAF; SIRT4; SMARCB1; KMT2A; SIRT2; SIRT1; HDAC6 2024-02-07 Pazopanib Y Y N N 2009 Y DB06589 L01EX03 CHEMBL477772 Advanced Renal Cell Carcinoma; Advanced Soft Tissue Sarcoma; Advanced Thyroid cancer KDR; NRAS; AURKB; PDGFRB; FLT1; KIT; LCK; PDGFRA; ALK; RET; HDAC2; AR; CYP2C8; CYP3A4; FGFR2; TP53; TNK2; UGT1A1; ABCG2; FLT4; MET; YES1; ABL1; CDK7; TAOK1; MTOR; FGFR1; MAP4K4; IGF1R; FGFR3; VHL; MAPK8; CXCL8; FYN; CSF1R; SCGB3A1; AURKA; PPARD; LTK; NEK2; NR1I2; PTK2; LIMK1; HLA-B; EWSR1; MAPK9; VEGFA; NF1 2024-02-07 Pegaspargase Y Y N Y 1994 N DB00059 L01XX24 CHEMBL2108546 Acute Lymphoblastic Leukaemias (ALL) HLA-DRB1; DOK5; LINC00251; ARHGAP28; HLA-DQB1; BMP7; GATA3 2024-02-07 Peginterferon Alfa-2b Y Y N N 2001 N DB00022 L03AB10 CHEMBL1201561 Melanomas HLA-DPA1; CYP2R1; IFNL3; IFNAR2; VDR; IFIT1; SLC6A4; IFNA2; DNAAF9; HLA-A; SLC28A2; MICB; HLA-C; IL21R; JAK2; OAS1; KIR2DS2; TUT7; CARD16; HLA-B; CASP1; IFNAR1; KLRK1; IL18; EGFR; IL6; CXCL10; CYP27B1; SLC29A1; SOCS3; CTLA4; OASL 2024-02-07 Pembrolizumab Y Y N Y 2014 N DB09037 L01FF02 CHEMBL3137343 Advanced Renal Cell Carcinoma; Cervical Cancers; Colorectal Cancers; Metastatic Melanoma; Metastatic Solid Tumors; Unresectable Melanoma; Urothelial carcinoma ureter metastatic; Locally advanced Urothelial Carcinoma; Locally advanced gastroesphageal juntion adenocarcinoma; Metastatic gastroesphageal juntion adenocarcinoma; Metastatic nonsquamous non-small cell lung cancer; Recurrent, metastatic Head and Neck Squamous Cell Carcinoma; Refractory, metastatic Non small cell lung cancer; Refractory, relapsed Hodgkin Lymphoma; Refractory, relapsed Mediastinal Large B-cell Lymphoma; Unresectable Solid Tumors MLH1; BRAF; IDH1; FBXW7; PTEN; CD274; PBRM1; HLA-DRA; JAK1; ARID1A; TP53; ERBB2; MDM4; MSH6; NRAS; PDCD1LG2; B2M; ROS1; CDK12; ALK; PDCD1; JAK2; KIT; POLE; EGFR; MDM2; KRAS; STK11 2024-02-07 Pemetrexed Y Y N N 2004 Y DB00642 L01BA04 CHEMBL225072 Mesothelioma; Ovarian Cancer; Pleural Mesotheliomas; Urothelial carcinoma ureter metastatic; Locally advanced nonsquamous non-small cell lung cancer; Metastatic nonsquamous non-small cell lung cancer; Recurrent, IV-B Cervical cancer; Unresectable Thymoma RRM1; XRCC1; GGH; MTHFR; ROS1; TYMS; FOLR3; ERCC2; MTHFD1; ALK; KRAS; SLC46A1; GART; ABCC2; PTEN; SLC19A1; ATIC; DHFR; EGFR 2024-02-07 Pemigatinib Y Y N N 2020 N DB15102 L01EN02 CHEMBL4297522 Unresectable, locally advanced Cholangiocarcinomas; Unresectable, metastatic Cholangiocarcinomas FGFR1; FGFR3; FGFR2 2024-02-07 Pentostatin N N Y N 1991 Y DB00552 L01XX08 CHEMBL1580 B-Lymphocytic, prolymphocytic leukemia (Kiel Classification) refractory; Chronic Lymphocytic Leukaemia (CLL); Hairy Cell Leukemia (HCL); Mycosis Fungoides (MF); Sezary Syndrome ADA; PRKAA1 2024-02-07 Pertuzumab Y Y N N 2012 N DB06366 L01FD02 CHEMBL2007641 Early Breast Cancer; Inflammatory Breast Cancer (IBC); Locally Advanced Breast Cancer (LABC); Metastatic Breast Cancer ERBB2; NRG1; ESR2; ESR1; EGFR; PGR; ERBB3 2024-02-07 Pertuzumab, Trastuzumab, Hyaluronidase Y Y N N 2020 Not found in DrugBank L01XY02 2021-10-28 Pipobroman N N Y N 1966 DB00236 L01AX02 CHEMBL1585 ALDH1A1; KDM4E; NFE2L2 2024-02-07 Pirarubicin N N N Japan N DB11616 L01DB08 CHEMBL2354444 USP1; MYCN; POLK; KMT2A; GLS; TP53; ABCC1; FEN1; HTT 2024-02-07 Pirtobrutinib Y Y N N 2023 N DB17472 L01EL05 CHEMBL4650485 Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma BTK 2024-02-07 Pixantrone Y N N N 2012 N DB06193 L01DB11 CHEMBL167731 Non-Hodgkin's Lymphoma, Relapsed; Refractory Non-Hodgkin's lymphoma TOP2A 2024-02-07 Polatuzumab Vedotin Y Y N N 2019 N DB12240 L01FX14 CHEMBL3301582 Diffuse Large B-Cell Lymphoma (DLBCL) TUBB4B; TUBB2A; CD79B; TUBA1A; TUBA3E; TUBA1C; TUBB2B; TUBB4A; TUBA3C; TUBB8; TUBB; TUBB1; TUBA1B; TUBB6; TUBB3; TUBA4A 2024-02-07 Polyestradiol Phosphate N N Y N 1957 DB09369 L02AA02 CHEMBL1201477 ESR1; AFP; NOS1 2024-02-07 Pomalidomide Y Y N N 2013 Y DB08910 L04AX06 CHEMBL43452 Refractory Multiple Myeloma CUL4A; DDB1; RBX1; CRBN 2024-02-07 Ponatinib Y Y N N 2012 N DB08901 L01EA05 CHEMBL1171837 Accelerated phase chronic myologenic leukemia; Acute Lymphoblastic Leukaemias (ALL); Chronic Phase Chronic Myeloid Leukemia; Blast phase Chronic myelocytic leukemia FLT3; PDGFRA; KIT; FGFR1; FGFR2; FGFR3; ABL1; FGFR4; PDGFRB; EML4; ABL2; BCR; BRAF; KRAS; ABI1; YES1; SRC; KDR; RET 2024-02-07 Porfimer Y Y N N 1995 N DB00707 L01XD01 CHEMBL1201481 Esophageal Cancers; Completely obstructive Non-small cell lung cancer; Microinvasive endobrachial Non-small cell lung cancer; Partially obstructive Non-small cell lung cancer 2020-09-17 Pralatrexate Y Y N N 2009 Y DB06813 L01BA05 CHEMBL1201746 Cutaneous T-Cell Lymphoma (CTCL); Relapsed Peripheral T-Cell Lymphoma; Refractory Peripheral T-cell Lymphoma Unspecified DHFR; RFC1; PDF 2024-02-07 Pralsetinib Y Y N N 2020 N DB15822 L01EX23 CHEMBL4297597 Metastatic RET-fusion Non Small Cell Lung Cancer RET; CCDC6; KIF5B; EML4 2024-02-07 Prednisolone Y Y N Y 1955 Y DB00860 S03BA02; S02BA03; S01CB02; S01BA04; R01AD02; H02AB06; D07XA02; D07AA03; C05AA04; A07EA01 CHEMBL131 Hypercalcemia of Malignancy; Leukemia, Acute; Malignant Lymphomas; Mycosis Fungoides (MF) TG; DSE; NFE2L2; MTHFR; CYP3A5; NR3C1; HMGB1; CD34; CYP3A4; RPS19; ALPP; BGLAP; BAX; G6PD; PNPLA3; TAT; ANXA1; PLG; AR; TSPYL1; FCGR3B; FCGR3A; LCAT 2024-02-07 Prednisone N Y Y N 1955 Y DB00635 H02AB07; A07EA03 CHEMBL635 Acute Lymphoblastic Leukaemias (ALL); Aggressive Lymphoma; Hypercalcemia of Malignancy; Leukemia, Acute; Leukemias; Malignant Lymphomas; Metastatic Castration Resistant Prostate Cancer; Mycosis Fungoides (MF) ATM; BMP7; DOK5; NCF4; MYC; NR3C1; MC2R; APOE; HSD17B10; NFATC1; TPMT; AR; CYP3A4; CHEK2; GSTA1; CTLA4; PALB2; PTPRC; CYP1A2; GSTM1; CYBA; ANXA1; ITGB2; CYP2D6; MBP; GSTP1; ABCB1; GATA3; BRIP1; LINC00251; CYP2C9; EDNRA; FANCA; CYP2C19; VWF; NOS3; CALCA; CDK12; SLC19A1; TG; CXCL12; IFNG 2024-02-07 Procarbazine N Y Y Y 1969 N DB01168 L01XB01 CHEMBL1321 Non-Hodgkin's Lymphoma (NHL); Oligodendrogliomas; Primary Central Nervous System Lymphoma (PCNSL); Stage III Hodgkin's Disease; Stage IV Hodgkin's Disease BAX; EPM2AIP1; ALOX15; CSF2; CYP1A2 2024-02-07 Quizartinib Y Y N N 2023 N DB12874 L01EX11 CHEMBL576982 Newly Diagnosed Acute Myeloid Leukemia (AML) PDGFRA; NRAS; JAK3; FGF2; PDGFRB; KIT; CBL; CSF1R; RET; IDH2; FLT3 2024-02-07 Racotumomab N N N Cuba, Argentina N DB13045 CHEMBL1743059 2020-09-17 Radium 223 Dichloride Y Y N N 2013 N DB08913 V10XX03 CHEMBL2107816 Castration resistant, metastatic Prostate cancer 2020-09-17 Raltitrexed N N Y Canada N 1996 N DB00293 L01BA03 CHEMBL225071 Advanced Colorectal Cancer; Pleural Mesotheliomas ALB; TYMS; DHFR; CDKN1B; CDK2; SLC19A1 2024-02-07 Ramucirumab Y Y N N 2014 N DB05578 L01FG02 CHEMBL1743062 Advanced Gastric Cancer; Advanced gastro-esophageal junction adenocarcinoma; Refractory, metastatic Colorectal cancer; Refractory, metastatic Non small cell lung cancer KDR; PDGFRA; ALK; KRAS; EGFR 2024-02-07 Ranimustine N N N Japan N DB13832 L01AD07 CHEMBL2105348 2020-09-22 Realgar-Indigo Naturalis Formulation N N N China Y 2009 Not found in DrugBank L01XX27 Acute promyelocytic leukaemia 2021-03-10 Regorafenib Y Y N N 2012 N DB08896 L01EX05 CHEMBL1946170 Hepatocellular Carcinoma; Metastatic Colorectal Cancer (MCRC); Metastatic Gastrointestinal Stromal Tumor; Locally advanced Gastrointestinal stromal tumor; Unresectable Gastrointestinal stromal tumor MAPK11; RET; ARAF; FGFR2; FLT4; BRAF; EPHA2; FRK; DDR2; ZHX2; TEK; FGFR3; RAF1; KDR; PDGFRB; KRAS; FLT1; FGFR1; PTEN; MAP2K1; NRAS; VEGFA; FBXW7; ABL1; PIK3CA; EGFR; NTRK1; PDGFRA; YES1; KIT; VHL 2024-02-07 Relatlimab , Nivolumab Y Y N N 2022 N DB14851 L01XY03 CHEMBL3990044; CHEMBL2108738 Metastatic Melanoma, Unresectable Melanoma 2024-02-07 Relugolix Y Y N N 2020 N DB11853 L02BX04 CHEMBL1800159 Advanced Prostate Cancer GNRHR; LHCGR 2024-02-07 Repotrectinib N Y N N 2023 N DB16826 L01EX28 CHEMBL4298138 locally active or metastatic non-small cell lung cancer NTRK1; ALK; EML4; ROS1; NTRK3 2024-02-07 Retifanlimab N Y N N 2023 N DB15766 L01FF10 CHEMBL4298037 Metastatic Locally Advanced Merkel Cell Carcinoma, Recurrent, locally advanced Merkel Cell Carcinoma PDCD1 2024-02-07 Ribociclib Y Y N N 2017 N DB11730 L01EF02 CHEMBL3545110 Advanced Breast Cancer; Metastatic Breast Cancer NRAS; BRAF; RB1; PGR; CDK4; CCND1; CDK6; CDKN2A; ALK; PIK3CA; PTEN; CCND2; ESR1; ESR2; SMARCA4; CCND3; ERBB2; JAK2 2024-02-07 Ripretinib Y Y N N 2020 N DB14840 L01EX19 CHEMBL4216467 Advanced Gastrointestinal Stromal Tumor (GIST) KIT; PDGFRA; PDGFRB 2024-02-07 Rituximab Y Y N Y 1997 N DB00073 L01FA01 CHEMBL1201576 Chronic Lymphocytic Leukaemia (CLL); Non-Hodgkin's Lymphoma (NHL) MS4A1; GSTA1; IL2; FCGR3A; FCGR2A; ABCB1; NCF4; TGFB1; TP53; CYBA; IL6; XIAP; CXCL12; CXCL13; RPS19 2024-02-07 Rituximab, Hyaluronidase N Y N N 1997 N DB00073 L01XC02 CHEMBL1201576 Chronic Lymphocytic Leukaemia (CLL); Non-Hodgkin's Lymphoma (NHL) MS4A1; GSTA1; IL2; FCGR3A; FCGR2A; ABCB1; NCF4; TGFB1; TP53; CYBA; IL6; XIAP; CXCL12; CXCL13; RPS19 2024-02-07 Romidepsin Y Y N N 2009 Y DB06176 L01XH02 CHEMBL343448 Refractory peripheral cutaneous T-cell lymphoma HDAC4; HDAC5; HDAC1; HDAC2; ERBB2; HDAC3; HDAC11; HDAC6; HDAC8; BRAF; KMT2A; CDKN1A; HDAC9; HDAC7; ADAMTSL4-AS1; ABCB1; CTAG1B; CDKN2D; HDAC10; BIRC5 2024-02-07 Rucaparib Y Y N N 2016 N DB12332 L01XK03 CHEMBL1173055 Advanced Ovarian Cancer PALB2; CYP1A2; BRCA1; RAD51D; PARP1; ATM; CHEK2; BRCA2; RAD51B; PRKD2; FANCA; PARP3; CDK12; DYRK1A; RAD51C; ATR; ARID1A; BRIP1; CDK1; PIM1; IDH1; CYP2D6; PTEN; YES1; PARP2 2024-02-07 Ruxolitinib Y Y N N 2011 N DB08877 L01EJ01 CHEMBL1789941 Post Polycythemia Vera Myelofibrosis; Refractory Polycythemia vera JAK2; JAK1; CSF3R; FLT3; BRAF; VHL; CYP3A4; CRLF2; SH2B3; TP53; IL7R; PLAUR; JAK3 2024-02-07 Sacituzumab Govitecan Y Y N N 2020 N DB12893 L01FX17 CHEMBL3545262 Metastatic Triple-negative Breast Cancer UGT1A1; TACSTD2; TOP1 2024-02-07 Selinexor Y Y N N 2019 N DB11942 L01XX66 CHEMBL3545185 Refractory Multiple Myeloma XPO1; TET2; TP53; FLT3 2024-02-07 Selpercatinib Y Y N N 2020 N DB15685 L01EX22 CHEMBL4559134 Advanced RET-fusion thyroid cancer; Advanced RET-mutant medullary thyroid cancer; Metastatic RET-fusion Non Small Cell Lung Cancer; Metastatic RET-fusion thyroid cancer; Metastatic RET-mutant medullary thyroid cancer RET; KIF5B; CCDC6 2024-02-07 Sipuleucel-T N Y N N 2010 N DB06688 L03AX17 CHEMBL1237024 Asymptomatic, metastatic hormone-refractory Prostate cancer; Minimally symptomatic, metastatic hormone-refractory Prostate cancer ACP3 2024-02-07 Sonidegib Y Y N N 2015 N DB09143 L01XJ02 CHEMBL2105737 Refractory, locally advanced Basal cell carcinoma SMO; SUFU; MYCN; FLT3; PTCH1 2024-02-07 Sorafenib Y Y N N 2005 Y DB00398 L01EX02 CHEMBL1336 Advanced Renal Cell Carcinoma; Gastrointestinal Stromal Tumors; Hemangiosarcoma; Unresectable Hepatocellular Carcinoma; Locally recurrent refractory to radioactive iodine treatment Thyroid carcinoma; Metastatic refractory to radioactive iodine treatment Thyroid carcinoma FLT1; JAK3; ARAF; DYRK3; RAF1; AURKB; PTPN6; RET; CYP2C9; SLC15A2; CDK8; VHL; HIF1A; NTRK2; ARID1A; PDGFRB; SLK; MAP2K1; BRAF; FGFR3; KRAS; YES1; IRAK1; NTRK1; PDGFRA; MAPK9; FGFR1; PIK3CA; MAPK13; MAPK12; NRAS; FLT4; EGFR; NTSR1; PLK4; KIT; UGT1A1; MAPK10; ZHX2; VEGFA; CSF1R; VEGFB; RPS6KB1; MAPK11; NF1; SRPK1; CYP3A4; MKNK2; AR; LYN; UGT1A9; IDH2; HMOX1; GMNN; MAPK7; HIPK4; MINK1; AXL; SLC22A1; ABCB1; ABCC2; ABCG2; AURKA; CYP2C8; BLK; MC4R; CYP2B6; SLCO1B1; TAOK1; CTNNB1; HIPK2; TNF; PTEN; LIMK1; CAMK2B; MAPK4; CBL; PAX8; MAPK8; MAP3K20; NTRK3; TP53; KDR; FGF3; NOS3; MAPK14; EPHA2; ABL1; MAPK6; FLT3; VEGFC; MAPK1; MAPK3; ATXN2; MAP4K5; NFE2L2 2024-02-07 Sotorasib Y Y N N 2021 N DB15569 L01XX73 CHEMBL4535757 Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer KRAS 2024-02-07 Streptozocin N Y N N 2005 N DB00428 L01AD04 CHEMBL1651906 Stage 4 islet cell carcinoma CTSD; KCNA2; MMP2; PRKAA1; GALP; BCL2; IGFBP1; PTGER4; HP; HRAS; CSF2; SI; PREP; VWF; MT1H; OGA; SST; CYP7B1; SFTPB; CDKN1B; THRSP; CD40; UCP1; LCAT; PIK3CA; RAMP3; TGFB1; TH; ENO2; ADCYAP1; SLC16A3; SLC5A1; S100B; NTRK1; ATF2; SSTR1; KCNJ11; DDIT3; TRPV1; SULT1A2; MYO9B; SLC2A5; SLC2A4; CYP2D6; HGF; ACP5 2024-02-07 Sunitinib Y Y N N 2006 Y DB01268 L01EX01 CHEMBL535 Advanced Renal Cell Carcinoma; Soft Tissue Sarcoma (STS); Thyroid Cancers; Metastatic Pancreatic Neuroendocrine Tumors; Refractory Gastrointestinal stromal tumor; Unresectable, locally advanced Pancreatic Neuroendocrine Tumors KDR; PDGFRB; RET; FLT3; KIT; FLT4; EWSR1; VEGFC; POR; PDGFRA; PDGFA; FGFR2; VEGFA; PDGFB; PTEN; NR1I2; CYP1A1; PTPRB; NR1I3; PDGFC; SLCO1B3; PDGFD; HIF1A; FGFR1; BAP1; NOS3; KDM5C; MKI67; CA9; HMOX1; PTPN12; VHL; CSF1R; PBRM1; FLT1; CYP3A4; CXCL8; YES1 2024-02-07 Tafasitamab Y Y N N 2020 N DB15044 L01FX12 CHEMBL4298047 Refractory Diffuse large B-cell lymphoma NOS; Relapsed Diffuse large B-cell lymphoma NOS CD19 2024-02-07 Tagraxofusp Y Y N N 2018 N DB14731 L01XX67 CHEMBL4297573 Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) EEF2; CSF2RB; IL3RA 2024-02-07 Talazoparib Y Y N N 2018 N DB11760 L01XK04 CHEMBL3137320 Locally Advanced Breast Cancer (LABC); Metastatic Breast Cancer BRCA2; PARP2; PARP1; BRCA1; PSMD4; ATRX; SLFN11; ERBB2; MYCN; PTEN; IDH2; CHEK2; FANCA; RAD51C; ARID1A; ATR; RAD51D; EGFR; PALB2; IDH1; ATM 2024-02-07 Talimogene Laherparepvec Y Y N N 2015 N DB13896 L01XX51 CHEMBL2108727 Unresectable Skin Lesion CSF2RA; CSF2 2024-02-07 Talquetamab Y Y N N 2023 N DB16678 L01FX29 CHEMBL4594503 Relapsed and Refractory Multiple Myeloma CD3G; CD3E; CD3D; GPRC5D 2024-02-07 Tamoxifen N Y Y Y 1977 Y DB00675 L02BA01 CHEMBL83 Breast Cancer; Desmoid Tumors; Endometrial Cancer; Invasive Breast Cancer; Invasive Breast Carcinoma; Metastatic Breast Cancer; Ovarian Cancer PGR; VDR; FMO3; ABCB1; ESR2; TP53; HEXB; ESR1; BRCA1; NR1I2; CYP2C9; MUC16; EDN1; ERBB2; PIK3CA; IDH1; NF1; CYP2B6; KLK3; CETP; ATXN2; GAPDH; CCND1; CYP19A1; COL18A1; EHMT2; LRMDA; E2F7; FMO1; KDM4A; MYOD1; ZNF423; PLD2; F5; BGLAP; TFF3; F2; GGT1; CBX1; NTRK1; UGT1A4; CYP2D6; DHFR; TYMS; TGFB1; NCOA1; RRAS2; GMNN; NCOA3; NRG1; TGM2; HSPB2; PIP; NFE2L2; CYP1A2; IGF1R; AURKA; BAZ2B; CCNA2; PLD1; CYP3A4 2024-02-07 Tazemetostat N Y N N 2020 N DB12887 L01XX72 CHEMBL3414621 Locally Advanced Epithelioid Sarcoma; Metastatic Epithelioid Sarcoma SMARCB1; ARID1A; SMARCA4; EZH2; KDM6A; FLT3; ATRX 2024-02-07 Tebentafusp Y Y N N 2022 N DB15283 L01XX75 CHEMBL4297990 Metastatic Uveal Melanoma (UM), Unresectable Uveal Melanoma PMEL; TRBV20OR9-2; CD3G 2024-02-07 Teclistamab Y Y N N 2022 N DB16655 L01FX24 CHEMBL4594505 Multiple Myeloma CD3E; TNFRSF17; CD3D; CD3G 2024-02-07 Tegafur, Gimeracil, Oteracil Y N N N 2011 DB09256 L01BC03; L01BC53 CHEMBL20883 Advanced Gastric Cancer DPYD; UMPS; EGFR; TYMS 2024-02-07 Tegafur, Uracil N N N Japan N DB09256 L01BC03; L01BC53 CHEMBL20883 Advanced Gastric Cancer DPYD; UMPS; EGFR; TYMS 2024-02-07 Temoporfin Y N N N 2001 N DB11630 L01XD05 CHEMBL500576 Advanced Head and Neck Squamous Cell Carcinoma 2020-09-17 Temozolomide Y Y N N 1999 Y DB00853 L01AX03 CHEMBL810 Advanced Melanoma; Glioblastomas; Primary Central Nervous System Lymphoma (PCNSL); Refractory Ewing Sarcoma; Refractory Neuroblastoma; Soft Tissue Sarcoma (STS); Advanced Neuroendocrine tumor; Refractory Anaplastic astrocytoma; Refractory, advanced Mycosis fungoides; Refractory, advanced Sezary Syndrome ATR; HDAC4; SLFN11; TP53; MGMT; BRCA2; MYC; GSTP1; MSH6; IDH1; H2AX; PRL; ATM; CSF2; ALK; PTEN; ATRX 2024-02-07 Temsirolimus Y Y N N 2007 Y DB06287 L01EG01 CHEMBL1201182 Advanced Renal Cell Carcinoma MTOR; PTPRD; PIK3CA; BRAF; KRAS; NR1I2; NF2; PTEN; FBXW7; ABCB1; CYP3A5; CTNNB1; VHL; FKBP1A; RPTOR 2024-02-07 Tepotinib Y Y N N 2021 N DB15133 L01EX21 CHEMBL3402762 Metastatic Non-Small Cell Lung Cancer ALK; EGFR; MET 2024-02-07 Thalidomide Y Y N Y 1998 N DB01041 L04AX02 CHEMBL468 Multiple Myeloma (MM); Waldenstrom's Macroglobulinemia (WM); Treatment naive multiple myeloma TNF; SULT1C4; DDB1; HGF; SPG7; NAT2; CHST3; PPARD; FGFR2; VWF; FGF2; CYP1A2; XRCC5; CTLA4; PTGS2; RPL13; F2R; NFKB1; HLA-B; VEGFA; CTNNB1; FCGR3B; SLC10A2; ABCC6; ATP7A; CYP2C19; ERCC1; CUL4A; CYP4B1; FCGR3A; RBX1; IL6R; MECOM; GSTT1; CRBN; SNORD68; ITGB2 2024-02-07 Thioguanine N Y N N 1966 N DB00352 L01BB03 CHEMBL727 Acute Nonlymphocytic Leukemia; Nonlymphocytic Acute myeloid leukemia ACHE; SLC28A3; IMPDH1; TPM3; AR; HBB; BMP7; TPMT; NUDT15; PRPS1; NAT1; GDA; NFE2L2; IMPDH2; IDH1; EHMT2; LINC00251; DOK5; PAX8; GATA3; NT5C2; HPGD; KDM4A; MGMT; MYC; GGH; XDH; ABCC4 2024-02-07 Thiotepa Y Y N N 1959 Y DB04572 L01AC01 CHEMBL671 Adenocarcinoma of the Ovaries; Breast Adenocarcinoma; Papillary transitional cell carcinoma of bladder; Malignant effusion AR; EHMT2; GSTP1; CYP2B6; TP53; VDR; HPGD; GMNN; ALDH1A1 2024-02-07 Tisagenlecleucel Y Y N N 2017 N DB13881 L01XX71 CHEMBL3301574 Refractory B-cell precursor acute lymphoblastic leukemia; Second or later relapsed B-cell precursor acute lymphoblastic leukemia CD19; MS4A1 2024-02-07 Tislelizumab Y N N China N 2023 DB14922 L01FF09 CHEMBL4297840 Unresectable, Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma PDCD1 2024-02-07 Tisotumab Vedotin N Y N N 2021 N DB16732 L01FX23 CHEMBL4297841 Recurrent or metastatic cervical cancer TUBB; TUBA3C; TUBB2A; TUBB4A; TUBB3; TUBA4A; TUBA1C; TUBA3E; TUBB4B; TUBB1; TUBB6; TUBA1A; F3; TUBB8; TUBB2B; TUBA1B 2024-02-07 Tivozanib Y Y N N 2017 N DB11800 L01EK03 CHEMBL1289494 Advanced Renal Cell Carcinoma; Renal Cell Adenocarcinoma FLT1; KDR; FLT4; YES1; NRAS; BRAF 2024-02-07 Topotecan Y Y N N 1996 Y DB01030 L01CE01 CHEMBL84 Acute Myeloid Leukemia (AML); Ewing's Sarcoma; Refractory Neuroblastoma; Metastatic Rhabdomyosarcoma; Recurrent, IV-B Cervical cancer; Refractory CNS lymphoma; Refractory CNS malignancy; Refractory, metastatic Ovarian cancer; Relapsed Small cell lung cancer USP1; PIK3CA; HBB; TOP1; NFE2L2; PLK1; ABCB1; HIF1A; PAX8; IDH1; TYMS; DDO; PTEN; ABCG2; AR; TOP1MT; RB1; TP53; ALK; MUC16; BDNF; TSG101; AKT1; ATRX; KMT2A 2024-02-07 Toremifene Y Y N N 1997 Y DB00539 L02BA02 CHEMBL1655 Desmoid Tumors; Metastatic Breast Cancer AR; TGFB1; ESR2; GMNN; KDM4A; PGR; CYP3A4; CYP1B1; CYP2D6; CD80; HNF4A; ESR1; PLIN1 2024-02-07 Toripalimab N Y N N 2023 N DB15043 L01FF13 CHEMBL4297843 Metastatic and Recurrent Nasopharyngeal Carcinoma PDCD1 2024-02-07 Trabectedin Y Y N N 2015 N DB05109 L01CX01 CHEMBL450449 Metastatic Leiomyosarcoma; Metastatic Liposarcoma; Relapsed platinum-sensitive Ovarian cancer; Unresectable Leiomyosarcoma; Unresectable Liposarcoma ABCB1; PARP1; FGFR2; ABCC2; TP53 2024-02-07 Trametinib Y Y N N 2013 N DB08911 L01EE01 CHEMBL2103875 Metastatic Melanoma; Unresectable Melanoma; Metastatic Non-small cell lung cancer with a BRAF V600E mutation; Pediatric low-grade glioma (LGG) with a BRAF V600E mutation; Locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation KRAS; NF1; HRAS; MAP2K2; MAP2K1; BRAF; MET; CDKN2A; CIC; VHL; KIT; ERBB3; ETV5; RB1; ETV4; EML4; ALK; ATM; MAP2K4; TP53; MAP2K5; RASA1; PIK3CA; ABL1; FGFR1; RET; RAF1; ETV1; CTNNB1; DNMT3A; G6PD; DUSP6; MAP2K3; PTEN; CSF3R; MAP2K6; ATXN1L; ARAF; NRAS; FGFR2; DDX43; MAP2K7; FLT3; PRKCH 2024-02-07 Trastuzumab Y Y N Y 1998 N DB00072 L01FD01 CHEMBL1201585 Breast Cancer; Early Breast Cancer; Inflammatory Breast Cancer (IBC); Locally Advanced Breast Cancer (LABC); Metastatic Adenocarcinoma of the Gastro-Esophageal Junction; Metastatic Adenocarcinoma of the Stomach; Metastatic Breast Cancer; Metastatic Gastric Adenocarcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma PGR; FCGR3A; KRAS; ANXA1; PIK3CA; ARID1A; ESR2; ERBB3; EPCAM; PPCDC; HGF; PTEN; IFNG; RNF8; ESR1; MET; FCGR2A; BIRC5; AKT2; EGFR; PIK3CG; RAD51C; HSPB2; MTHFR; ERBB2 2024-02-07 Trastuzumab Deruxtecan Y Y N N 2019 N DB14962 L01FD04 CHEMBL4297844 HER2 Positive Breast Cancers ERBB2; TOP1 2024-02-07 Trastuzumab Emtansine Y Y N N 2013 N DB05773 L01FD03 CHEMBL1743082 Refractory, metastatic Non small cell lung cancer ERBB2; TUBA1A; TUBB8; TUBA1B; TUBA1C; TUBB2B; TUBB6; TUBB4B; PIK3CA; TUBA3C; TUBB2A; TUBB1; TUBB; TUBA3E; TUBA4A; TUBB4A; TUBB3 2024-02-07 Trastuzumab, Hyaluronidase Y Y N N 1998 N DB00072 L01XC03 CHEMBL1201585 Breast Cancer; Early Breast Cancer; Inflammatory Breast Cancer (IBC); Locally Advanced Breast Cancer (LABC); Metastatic Adenocarcinoma of the Gastro-Esophageal Junction; Metastatic Adenocarcinoma of the Stomach; Metastatic Breast Cancer; Metastatic Gastric Adenocarcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma PGR; FCGR3A; KRAS; ANXA1; PIK3CA; ARID1A; ESR2; ERBB3; EPCAM; PPCDC; HGF; PTEN; IFNG; RNF8; ESR1; MET; FCGR2A; BIRC5; AKT2; EGFR; PIK3CG; RAD51C; HSPB2; MTHFR; ERBB2 2024-02-07 Tremelimumab Y Y N N 2022 N DB11771 L01FX20 CHEMBL2108658 Metastatic Non-Small Cell Lung Cancer, Unresectable Hepatocellular Carcinoma (HCC) CTLA4 2024-02-07 Tretinoin N Y Y N 1971 Y DB00755 D10AD01; L01XF01 CHEMBL38 FAB classification M3 Acute promyelocytic leukemia RARG; BIRC5; ADH1C; TBP; MDK; MST1; FUS; CDKN1B; NR2C1; LIF; RARA; FLT3; CEACAM1; NOS1; ALPL; APOE; DUSP6; TGFB1; HES1; CALR; SMARCA4; RARB; BAX; VDR; NFE2L2; NRIP1; CYP2C9; MYCN; TG; BCL2; IL10; RXRB; SPP1; TGFBR3; ERVK2; GLI1; TP73; PTPRZ1; AMH; HOXD1; ITGB2; PML; PRL; CYP3A5; TPO; HAS3; SLC2A1; RARRES1; HIF1A; APOA1; IL1R1; HOXB1; CXCL8; IFNG; FAS; RB1; KLK3; PTCH1; XIAP; RPE65; NPM1; ALDH1A2; KAT2A; WT1; MYOD1; THBS1; BHLHE40; CD55; USP1; OCLN; HSPA8; RXRA; SHH; RAB40B; NR4A1; SFTPA1; RET; EGR2; P2RY2; EHMT2; SMAD2; MAPK8; RXRG; TSPYL2 2024-02-07 Trifluridine, Tipiracil Y Y N N 1980 Y DB00432 L01BC59; S01AD02 CHEMBL1129 Metastatic Colorectal Cancer (MCRC) ERBB2; SLC29A1; TP53 2024-02-07 Triptorelin N Y Y N 2000 N DB06825 L02AE04 CHEMBL1201334 Advanced Prostate Cancer STS; GNRHR 2024-02-07 Trofosfamide N N Y N DB12902 L01AA07 CHEMBL462019 Non-Hodgkin's lymphoma CYP2B6 2024-02-07 Tucatinib Y Y N N 2020 N DB11652 L01EH03 CHEMBL3989868 Breast Cancer; Unresectable Breast Cancer ERBB2 2024-02-07 Umbralisib N Y N N 2021 N DB14989 L01EX25 CHEMBL3948730 B-cell Follicular Lymphoma; Marginal Zone Lymphoma (MZL) PIK3CD; PIK3CG 2024-02-07 Valrubicin N Y N N 1998 Y DB00385 L01DB09 CHEMBL1096885 In situ BCG-refractory Bladder carcinoma TOP2A; AR 2024-02-07 Vandetanib Y Y N N 2011 N DB05294 L01EX04 CHEMBL24828 Metastatic Medullary Thyroid Cancer; Locally advanced Medullary thyroid cancer BTK; EGFR; KRAS; KDR; ATM; RET; ABL1; EPHA5; EPHB4; EPHA3; TYRO3; FLT1; SRC; EPHA4; ALK; EPHB2; MAP2K1; ERBB3; LRRK2; LTK; EPHA10; MAP2K2; ROCK2; PTEN; IDH1; MAPK14; EPHB1; EPHA6; EPHA2; LCK; FLT4; MAP4K4; HTT; AURKB; MAP4K5; EPHB3; PTK6; EPHA1; GMNN; PDGFRA; ACVR1; ERBB2; PDGFRB; AXL; TEK; YES1; ERBB4; FYN; MTOR; FGFR1; EPHA7; APC; EPHB6; EPHA8 2024-02-07 Vemurafenib Y Y N N 2011 N DB08881 L01EC01 CHEMBL1229517 Metastatic Melanoma; Unresectable Melanoma; Refractory Non-small cell lung cancer MET; MAP2K1; BRAF; PIK3CA; AKT1; CYP3A4; PTEN; AKT3; STAG3; ABCB1; RAC1; CIC; TF; YES1; MITF; MAP2K2; CYP3A; TET2; FGFR2; RB1; PREX2; ATXN1L; NF1; TP53; CDKN2A; CYP1A2; STAG2; SOX10; CBL; HRAS; CHEK2; PIK3R2; KRAS; NRAS 2024-02-07 Venetoclax Y Y N N 2016 N DB11581 L01XX52 CHEMBL3137309 Chronic Lymphocytic Leukaemia (CLL); Small Lymphocytic Lymphoma NPM1; FLT3; IDH2; BCL2; IGH; ALK; IDH1; PTEN; KMT2A; NRAS; PIK3CA; KDM6A; ATM; ABL1; BRAF; TP53 2024-02-07 Vinblastine N Y Y Y 1965 Y DB00570 L01CA01 CHEMBL159 Advanced Soft Tissue Sarcoma; Cancer, Bladder; Kaposi's sarcoma; Lymphoma, Hodgkins; Metastatic Melanoma; Non-Small Cell Lung Carcinoma (NSCLC); Advanced Alibert-Bazin syndrome; Advanced Testicular cancer; Histiocytic lymphoma; Refractory Breast cancer TUBB8; TUBB2A; TUBB3; TUBB1; TUBA1C; TUBB6; TUBA1B; NR1I2; CGA; TUBA3C; GMNN; TUBB4A; TUBA4A; PTHLH; TUBB4B; TUBA3E; KLK3; TRH; GSTM1; TBXA2R; TUBB; ABCB4; TUBA1A; NOP2; TUBB2B; BRAF; CDKN1A; MMP2; CYP3A4; TUBA3D; NF1; ABCB1; CSF2 2024-02-07 Vincristine N Y Y Y 1965 Y DB00541 L01CA02 CHEMBL90555 Acute Lymphoblastic Leukaemia Recurrent; Acute Lymphocytic Leukemia (ALL); Choriocarcinoma; Chronic Lymphocytic Leukaemia (CLL); Ewing's Sarcoma; Hepatoblastomas; Kaposi's sarcoma; Lymphoma, Hodgkins; Multiple Myeloma (MM); Neuroblastomas; Non-Hodgkin's Lymphoma (NHL); Ovarian germ cell tumour; Pheochromocytomas; Retinoblastoma; Rhabdomyosarcomas; Small Cell Lung Cancer (SCLC); Wilms' tumor; Advanced Thymoma XDH; BCR; TUBA1C; TUBB3; BAHD1; TUBA3E; TUBA3C; COCH; TUBA4A; BMP7; CYP3A4; NOS3; FGF2; ABCC1; TUBB2A; ABCB4; CP; MRPL47; NRG1; CAPG; PIK3CA; TUBB4A; PNPLA3; CXCL12; DOK5; VWF; GATA3; SLC5A7; LINC00251; NCF4; SYNE2; TUBB4B; SMAD3; BCL2; RALBP1; TUBB6; TUBA3D; FCGR3A; AR; MTR; ABCC3; CEP72; CDKN1B; TYMS; ABCC10; ABCC2; MTHFR; TUBB1; ABL1; MYCN; ODC1; AFP; BDNF; TUBB2B; TP73; GMNN; ABCB1; SRI; ACTG1; NKAIN3; TOP2A; GSTA1; TUBB8; HSPB2; TUBB; NTF3; NR1I2; PIK3CG; TUBA1A; CYBA; TUBA1B 2024-02-07 Vincristine Liposome N Y N N 2012 Y DB00541 L01CA02 CHEMBL501867 Acute Lymphoblastic Leukaemia Recurrent; Acute Lymphocytic Leukemia (ALL); Choriocarcinoma; Chronic Lymphocytic Leukaemia (CLL); Ewing's Sarcoma; Hepatoblastomas; Kaposi's sarcoma; Lymphoma, Hodgkins; Multiple Myeloma (MM); Neuroblastomas; Non-Hodgkin's Lymphoma (NHL); Ovarian germ cell tumour; Pheochromocytomas; Retinoblastoma; Rhabdomyosarcomas; Small Cell Lung Cancer (SCLC); Wilms' tumor; Advanced Thymoma TUBA1B; TUBB8; TUBB2A; TUBA1A; NR0B1; TUBA3E; TUBB3; TUBB1; HIF1A; TUBB2B; ALK; TUBB; TUBA1C; GMNN; TUBA3C; TUBB4A; TUBB6; TUBB4B; TUBA4A 2024-02-07 Vindesine N N Y N 1979 N DB00309 L01CA03 CHEMBL238071 Acute Lymphocytic Leukemia (ALL); Melanoma, Malignant ABCB1; CYP3A4; TUBB; TUBB1 2024-02-07 Vinflunine Y N N N 2009 N DB11641 L01CA05 CHEMBL2110725 Transitional Cell Carcinoma of the Urothelial Tract; Metastatic Transitional Cell Carcinoma of the Urothelial Tract TUBB2B; TUBB8; TUBA1C; TUBA1A; TUBB6; TUBA3E; TUBB2A; TUBB1; TUBA4A; TUBA1B; TUBB4A; TUBB; TUBB4B; TUBA3C; TUBB3 2024-02-07 Vinorelbine N Y Y Y 1994 Y DB00361 L01CA04 CHEMBL553025 Advanced Non Small Cell Lung Cancer; Esophageal Cancers; Locally Advanced Non-Small Cell Lung Cancer; Metastatic Breast Cancer; Recurrent Cervical Cancer; Soft Tissue Sarcoma (STS); Recurrent, IV-B Cervical cancer TUBB4B; TUBB3; RRM1; TUBA3D; CASP7; TUBA1A; TUBB6; TUBB2A; TUBA1C; APC; TUBA3E; TUBB4A; TUBB; SMARCA4; BAX; CSF2; TUBB2B; TUBB1; STMN1; TUBA3C; TUBB8; TUBA4A; BRCA1; XRCC1; TUB; TUBA1B 2024-02-07 Vismodegib Y Y N N 2012 N DB08828 L01XJ01 CHEMBL473417 Locally Advanced Basal Cell Carcinoma; Metastatic Basal cell carcinoma PTCH1; SMO; SHH 2024-02-07 Vorinostat N Y N N 2006 N DB02546 L01XH01 CHEMBL98 Persistent Cutaneous T-Cell Lymphoma; Progressive Cutaneous T-cell lymphoma; Recurrent Cutaneous T-cell lymphoma HDAC2; TUBB1; HDAC4; HDAC8; HDAC11; TUBB2A; TUBA3E; GNA11; PAX8; BIRC5; HDAC1; HDAC10; BRAF; NR0B1; HDAC6; ERBB2; BAP1; TUBB4A; TUBB; TUBB8; HDAC7; TUBA1A; NFE2L2; TUBA3C; HDAC3; TUBA1B; UGT2B17; TUBB3; PTEN; ACE; TUBA1C; TUBA3D; TUBA4A; MYC; TUBB4B; FBXW7; CFTR; TUBB2B; TUBB6; IDH1; HDAC5; HDAC9; CHD4; TP53; RB1; GMNN 2024-02-07 Zanubrutinib Y Y N N 2019 N DB15035 L01EL03 CHEMBL3936761 Mantle Cell Lymphoma (MCL) BTK; TP53 2024-02-07